Page last updated: 2024-11-04

hydralazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Hydralazine is a vasodilator that directly relaxes vascular smooth muscle, lowering blood pressure. It is primarily used to treat hypertension, particularly in patients with high blood pressure that is not effectively controlled by other medications. Hydralazine's synthesis involves a complex multi-step process starting with phthalic anhydride. The compound exhibits antihypertensive effects by activating K+ channels and inhibiting Ca2+ influx in vascular smooth muscle cells. It is studied extensively to understand its mechanism of action, optimize its therapeutic use, and explore its potential in treating other conditions like heart failure. Despite its effectiveness, hydralazine can cause side effects such as headaches, dizziness, and lupus-like syndrome in some patients. It is generally considered safe and effective when used as prescribed.'

Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3637
CHEMBL ID276832
CHEBI ID5775
SCHEMBL ID7810
MeSH IDM0010676

Synonyms (146)

Synonym
LS-13412
BRD-K82103381-003-03-7
apressin
wln: t66 cnnj bmz
hidralazin
hypophthalin
hydrallazine
hydrazinophthalazine
ciba 5968
hydralazin
nsc126699
apresolin
1-hydrazinophthalazine ,
aprezolin
ba 5968
hipoftalin
nsc-126699
c-5968 ,
c-5068 ,
phthalazine, 1-hydrazino-
1(2h)-phthalazinone, hydrazone
OPREA1_207681
DIVK1C_000117
KBIO1_000117
NCIOPEN2_001484
SPECTRUM_000875
IDI1_000117
lopac-h-1753
cas-304-20-1
NCGC00015501-02
NCGC00015501-01
OPREA1_416878
BSPBIO_002130
LOPAC0_000593
PRESTWICK2_000169
SPECTRUM5_000822
brn 0132615
hydrallazin
hidralazina [spanish]
hydralazine [inn:ban]
apressin (pharmaceutical)
nsc 126699
idralazina [dcit]
praparat 5968
hydralazinum [inn-latin]
idralazina [italian]
c 5968
1(2h)-phthalazinone hydrazone
hidralazina [inn-spanish]
einecs 201-680-3
ccris 5385
hydralazine
C07040
86-54-4
(1z)-1(2h)-phthalazinone hydrazone
idralazina
phthalazin-1-ylhydrazine
(2h)-phthalazinone hydrazone
DB01275
6-hydralazine
1-phthalazinylhydrazine
hydrazone 1(2h)-phthalazinone
EC-000.1838
KBIOSS_001355
KBIOGR_000349
KBIO2_006491
KBIO2_003923
KBIO3_001350
KBIO2_001355
SPBIO_000977
NINDS_000117
SPBIO_001958
SPECTRUM4_000005
PRESTWICK0_000169
SPECTRUM2_000969
SPECTRUM3_000455
PRESTWICK1_000169
NCGC00162199-01
NCGC00015501-05
rptusvtufvmdqk-uhfffaoysa-
inchi=1/c8h8n4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5h,9h2,(h,11,12)
hydralazinum
CHEBI:5775 ,
hidralazina
hydralazine polistirex
CHEMBL276832
hlz ,
hydralazine (inn)
D08044
hidral (tn)
FT-0669282
AKOS000122609
cas_86-54-4
nsc_3637
bdbm81461
STK246900
(1e)-1-hydrazinylidene-1,2-dihydrophthalazine
CCG-204682
1-hydrazinylphthalazine
NCGC00015501-06
NCGC00015501-04
NCGC00015501-03
59275-69-3
26nak24ls8 ,
unii-26nak24ls8
5-25-17-00412 (beilstein handbook reference)
NCGC00015501-07
EPITOPE ID:137349
1-hydrazinylidene-1,2-dihydrophthalazine
gtpl7326
hydralazine [iarc]
dihydralazine sulfate, hydrated impurity b [ep impurity]
hydralazine [who-dd]
hydralazine [mi]
hydralazine [inn]
hydralazine [vandf]
hidral
(e)-1-hydrazono-1,2-dihydrophthalazine
SCHEMBL7810
AB01274815-01
1(2h)-phthalazinone hydrazone #
AB00053483_03
AB01274815_02
DTXSID4023129 ,
AKOS028109138
1-hydrazonophthalazine
phthalazone hydrazone
SBI-0050575.P004
'hydralazine; phthalazin-1-ylhydrazine'
Q419987
apresolin; apresoline; apressin
SDCCGSBI-0050575.P005
NCGC00015501-17
A914301
A916276
(1e)-1-hydrazono-1,2-dihydrophthalazine
AKOS016843064
discontinued see: h716531
HY-B0464A
CS-0013620
EN300-34025
hydralazinum (inn-latin)
dtxcid703129
hydralazine (iarc)
c02db02
hidralazina (inn-spanish)

Research Excerpts

Overview

Hydralazine is a vasodilator used to treat hypertension, pre-eclampsia, and heart failure. It has been associated with drug-induced lupus erythematosus (DIL) as well as ANCA-associated vasculitis (AAV)

ExcerptReferenceRelevance
"Hydralazine is an antihypertensive agent and may act as a xanthine oxidase (XO) inhibitor to reduce uric acid levels in a mouse renal injury model."( Antioxidation and Nrf2-mediated heme oxygenase-1 activation contribute to renal protective effects of hydralazine in diabetic nephropathy.
Chang, TT; Chen, C; Chen, JW; Chiang, CH; Lee, HJ; Lin, SC, 2022
)
1.66
"Hydralazine is a vasodilator used to treat hypertension, pre-eclampsia, and heart failure. "( A review on the clinical pharmacokinetics of hydralazine.
Alqahtani, F; Ashraf, W; Hussain, I; Imran, I; Khalid, S; Majeed, A; Rasool, MF; Rehman, AU; Saeed, H; Shahzad Qamar, A; Zamir, A, 2022
)
2.42
"Hydralazine is an FDA-approved drug used in the treatment of hypertension, heart failure and cancer."( Hydralazine targets cAMP-dependent protein kinase leading to sirtuin1/5 activation and lifespan extension in C. elegans.
Dehghan, E; Goodarzi, M; Lin, R; Mirzaei, H; Saremi, B, 2019
)
2.68
"Hydralazine is a common vasodilator which has been used for the treatment of hypertension and heart failure. "( Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary-renal syndrome: a case report.
Al-Abdouh, A; Bekele, A; Garcia, P; Seid, H; Siyal, AM, 2020
)
3.44
"Hydralazine is a common arterial vasodilator used in the management of congestive heart failure and hypertension. "( Severe cutaneous presentation of hydralazine-induced ANCA vasculitis without renal or pulmonary involvement, complicated by DIC.
Avelino, ARM; Huo, MX; Singh, G, 2021
)
2.35
"Hydralazine is a commonly prescribed antihypertensive agent. "( Hydralazine-induced liver injury: a review and discussion.
Bhardwaj, M; Bhardwaj, NJ; Cueto, K; Killeen, TC, 2021
)
3.51
"Hydralazine is an antihypertensive medication that has been associated with drug-induced lupus erythematosus (DIL) as well as ANCA-associated vasculitis (AAV). "( Hydralazine-associated vasculitis: Overlapping features of drug-induced lupus and vasculitis.
Kumar, B; Lenert, P; Strouse, J; Suneja, M; Swee, M, 2018
)
3.37
"Hydralazine is a direct-acting vasodilator, which has been used in treatment for hypertension (HTN) since the 1950s. "( Hydralazine-associated adverse events: a report of two cases of hydralazine-induced ANCA vasculitis.
Asif, A; Costanzo, EJ; Dounis, H; Haj, RA; Patel, M; Seyedali, S; Zuckerman, R,
)
3.02
"Hydralazine is a commonly used anti-hypertensive medication. "( Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis.
Edrees, F; Gaut, JP; Kudose, S; Paley, MA; Ranganathan, P; Vijayan, A,
)
1.86
"Hydralazine is an FDA-approved antihypertensive agent which has been utilized for years either alone or in combination with other medications especially the beta-blockers. "( Electrocardiographic Changes Following Acute Hydralazine Overdose.
Ahrari, Y; Akbari-Rad, M; Eshraghi, A; Esmaeili, A; Firoozi, A; Vahabzadeh, M, 2019
)
2.22
"Hydralazine is a medication that has been used to manage hypertension and heart failure. "( Hydralazine associated pauci-immune glomerulonephritis.
Baiswar, S; Suneja, M; Vogelgesang, SA, 2014
)
3.29
"Hydralazine is an effective antihypertensive drug which acts by vasodilatation. "( Hydralazine-induced toxic epidermal necrolysis in a patient on continuous ambulatory peritoneal dialysis.
Chan, JC; Yap, DY; Yeung, CK, 2014
)
3.29
"Hydralazine is an inhibitor of DNA methyltransferases, whereas valproate interferes with histone deacetylation. "( Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure.
Cedillo-Carvallo, B; Dueñas-González, A; Estrada-Marín, L; Garcés-Eisele, SJ; Guzmán-García, MO; Juárez-Calderón, M; Reyes-Núñez, V; Ruiz-Argüelles, A; Vázquez-Pérez, R, 2014
)
2.07
"Hydralazine (4) is an antihypertensive agent that displays both mutagenic and epigenetic properties. "( Covalent adduct formation between the antihypertensive drug hydralazine and abasic sites in double- and single-stranded DNA.
Gates, KS; Lewis, CD; Melton, D; Price, NE, 2014
)
2.09
"Hydralazine is a commonly used oral antihypertensive agent. "( Acute Cholestatic Liver Injury From Hydralazine Intake.
Harati, H; Rahmani, M; Taghizadeh, S,
)
1.85
"Hydralazine is a stable DNA methylation inhibitor that has minimal toxicity in vitro and in vivo."( Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.
Song, Y; Zhang, C, 2009
)
2.52
"Hydralazine is a direct-acting vasodilator which has been used for the treatment of hypertension since the 1950's."( Hydralazine for essential hypertension.
Kandler, MR; Mah, GT; Stabler, SN; Tejani, AM, 2010
)
2.52
"Hydralazine is a commonly used drug for treatment of hypertension and is known to cause drug-induced lupus erythematosus. "( Hydralazine-induced ANCA vasculitis with pulmonary renal syndrome: a rare clinical presentation.
Kaw, D; Malhotra, D; Marina, VP, 2012
)
3.26
"Hydralazine is a direct-acting vasodilator which has been used for the treatment of hypertension since the 1950's."( Hydralazine for essential hypertension.
Kandler, MR; Mah, GT; Salzwedel, DM; Stabler, SN; Tejani, AM, 2011
)
2.53
"Hydralazine is a potent antihypertensive drug and can scavenge acrolein efficiently."( Attenuation of mouse somatic and emotional inflammatory pain by hydralazine through scavenging acrolein and inhibiting neuronal activation.
Bai, L; Dong, YL; Huang, J; Li, YQ; Wang, LY; Wang, W; Wang, XY; Wu, SX,
)
1.09
"Hydralazine hydrochloride is an antihypertensive used alone or in combination with isosorbide nitrate for the treatment of congestive heart failure. "( Coated hydralazine hydrochloride beads for sustained release after oral administration.
Iqbal, Z; Kouba, C; Mughal, MA; Neau, SH; Saripella, KK, 2013
)
2.29
"Hydralazine is a hydrazine derivative used clinically as a vasodilator and antihypertensive agent. "( Effects of hydrazine derivatives on vascular smooth muscle contractility, blood pressure and cGMP production in rats: comparison with hydralazine.
Alvarez, E; Fernández, G; Medina, M; Orallo, F; Vidrio, H, 2003
)
1.97
"Hydralazine is an efficient reactive oxygen species (ROS) scavenger and an inhibitor of O2- generation."( The oxidative stress concept of nitrate tolerance and the antioxidant properties of hydralazine.
Daiber, A; Hink, U; Mollnau, H; Mülsch, A; Münzel, T; Oelze, M; Warnholtz, A, 2005
)
1.27
"Hydralazine is a smooth muscle relaxant and a potent arteriolar dilator. "( Hydralazine in heart failure.
Chatterjee, K, 1983
)
3.15
"Hydralazine is an effective antihypertensive drug that has come to be used in restricted dosage (not more than 200 mg daily) because of its risk of inducing the lupus syndrome."( The lupus syndrome induced by hydralazine: a common complication with low dose treatment.
Cameron, HA; Ramsay, LE, 1984
)
1.28
"Hydralazine appears to be a useful and effective drug to increase heart rate in patients with SSB."( Hydralazine in the management of symptomatic sinus bradycardia.
Gotsman, MS; Lewis, BS; Rod, JL; Weiss, AT, 1981
)
2.43
"Hydralazine is an antihypertensive drug that elicits andti-nuclear antibodies in patients as an adverse effect. "( Triplex-DNA stabilization by hydralazine and the presence of anti-(triplex DNA) antibodies in patients treated with hydralazine.
Adams, LE; Hess, EV; Seibold, JR; Thomas, TJ, 1995
)
2.03
"Hydralazine is a potent SSAO inhibitor and pretreatment with this irreversible inactivator resulted in a nearly complete loss of radioactive deposits in the tissues."( An autoradiographic method of visualising semicarbazide-sensitive amine oxidase activity in mouse tissue sections.
Ekblom, J; Garpenstrand, H; Grönvall, JL; Oreland, L, 2000
)
1.03
"Hydralazine is an antihypertensive vasodilator agent. "( Pharmacokinetics of hydralazine, apparent hydralazine and hydralazine pyruvic acid hydrazone in humans.
Haegele, KD; Ludden, TM; McNay, JL; Shepherd, AM; Talseth, T, 1979
)
2.03
"Hydralazine (Hyd) is a vaso-active drug that significantly affects the nature of blood flow in tumors. "( [Hydralazine-induced enhancement of hyperthermia treatment in vivo].
Akagi, K; Hasegawa, T; Oshima, T; Tanaka, Y, 1992
)
2.64
"Hydralazine is a vasodilator antihypertensive drug that has been in use for many years. "( Effect of food on oral availability of apresoline and controlled release hydralazine in hypertensive patients.
Jackson, SH; Jamieson, MJ; Ludden, LK; Ludden, TM; Muir, KT; Rogers, D; Shepherd, AM; Woodworth, J, 1990
)
1.95
"Hydralazine is a peripheral vasodilator used as an antihypertensive agent. "( Effects of hydralazine on the blood flow in RIF-1 tumors and normal tissues of mice.
Lin, JC; Song, CW, 1990
)
2.11
"Hydralazine is an antihypertensive drug which theoretically could increase tumour temperatures during hyperthermia via reduction in tumour blood flow from a vascular 'steal' phenomenon. "( The use of hydralazine to manipulate tumour temperatures during hyperthermia.
Acker, JC; Clegg, S; Dewhirst, MW; Leopold, K; Oleson, JR; Page, RL; Prescott, DM; Rosner, G; Samulski, TV; Thrall, DE,
)
1.96
"Hydralazine is a peripheral vasodilator, currently used clinically as an antihypertensive agent, which has been reported to be able to reduce tumour blood flow and increase the degree of tumour hypoxia."( Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo.
Christensen, KL; Horsman, MR; Overgaard, J,
)
2.3
"Hydralazine is a potent arteriolar dilator, which increases cardiac output in patients with heart failure. "( Correlation between effects of hydralazine on force and on the adenyl cyclase system of ventricular myocardium in dogs and cats.
Blumlein, S; Elazar, E; Har-Zahav, Y; Nerinsky, R; Neufeld, HN; Parmley, WW; Rabinowitz, B, 1986
)
2
"Dihydralazine is a substrate of the human N-acetyltransferase. "( The influence of the acetylator phenotype for the clinical use of dihydralazine.
Biebler, KE; Donner, I; Franke, G; Hüller, H; Kairies, M; Kallwellis, R; Scherber, A; Siegmund, W, 1985
)
1.23
"Hydralazine is a potent irreversible inhibitor of the semicarbazide-sensitive amine oxidase (SSAO) found in brown fat. "( The interaction of hydralazine with a semicarbazide-sensitive amine oxidase in brown adipose tissue of the rat. Its use as a radioactive ligand for the enzyme.
Barrand, MA; Callingham, BA, 1985
)
2.04

Effects

Hydralazine has shown renoprotective effects in multiple kidney diseases and was shown to be a potent xanthine oxidase (XO) inhibitor. It is widely used for treating hypertension, particularly in patients with renal failure.

ExcerptReferenceRelevance
"Hydralazine has shown renoprotective effects in multiple kidney diseases and was shown to be a potent xanthine oxidase (XO) inhibitor."( Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease.
Chang, TT; Chen, C; Chen, JW; Chiang, CH; Fang, SY; Lin, SC, 2023
)
1.89
"Hydralazine has been recently shown to promote lifespan in C."( Hydralazine targets cAMP-dependent protein kinase leading to sirtuin1/5 activation and lifespan extension in C. elegans.
Dehghan, E; Goodarzi, M; Lin, R; Mirzaei, H; Saremi, B, 2019
)
2.68
"Hydralazine has been reported as a selective mechanism-based inactivator of aldehyde oxidase (AO) and it is widely used in the pharmaceutical industry for reaction phenotyping to estimate fraction metabolized by AO and to identify AO substrates. "( Evaluation of Cytochrome P450 Selectivity for Hydralazine as an Aldehyde Oxidase Inhibitor for Reaction Phenotyping.
Di, L; Johnson, N; Yang, X, 2019
)
2.21
"Hydralazine has been widely used for treating hypertension, particularly in patients with renal failure. "( Hydralazine-induced cholestatic hepatitis.
Cucco, R; Hammad, R; Hassan, A; Niranjan, S,
)
3.02
"Hydralazine has been shown to reverse doxorubicin resistance in a model of breast cancer."( DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells.
Candelaria, M; Chavez-Blanco, A; de la Cruz-Hernandez, E; Diaz-Chavez, J; Dominguez, G; Duenas-Gonzalez, A; Gonzalez-Fierro, A; Perez-Cardenas, E; Soto-Reyes, E; Taja-Chayeb, L; Trejo-Becerril, C; Trujillo, JE, 2012
)
1.34
"Hydralazine has been shown to prevent tolerance in experimental and clinical studies, all of which may be at least in part secondary to antioxidant properties of this compound."( Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure.
Bachschmid, M; Coldewey, M; Daiber, A; Huth, C; Kaiser, K; Mülsch, A; Münzel, T; Nazirisadeh, Y; Oelze, M; Schildknecht, S; Tsilimingas, N; Ullrich, V, 2005
)
2.49
"Hydralazine has been shown to decrease blood pressure effectively in hypertensive emergencies of pregnancy."( Treatment of hypertensive emergencies of pregnancy.
Nissen, JC,
)
0.85
"Oral hydralazine has been shown to be effective in decreasing pulmonary arteriolar resistance and increasing cardiac output in some patients with primary pulmonary hypertension. "( Hemodynamics at rest and during exercise after oral hydralazine in patients with cor pulmonale.
Peter, RH; Rubin, LJ, 1981
)
1.03
"Hydralazine has been widely used in treatment of hypertension in eclampsia and preeclampsia, and its safety has been demonstrated in these patients."( Management of hypertensive urgencies and emergencies.
Abdelwahab, W; Frishman, W; Landau, A, 1995
)
1.01
"Hydralazine has been shown to reduce mortality in patients with congestive heart failure when given concomitantly with isosorbide dinitrate. "( Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug.
Berrington, WR; Freeman, BA; Harrison, DG; Kurz, S; Münzel, T; Rajagopalan, S; Thoenes, M; Thompson, JA, 1996
)
3.18
"Hydralazine has been known to cause a lupus-like syndrome that can produce the clinical manifestations of SLE."( Hydralazine-induced lupus and vocal fold paralysis.
Clayton, MI; Hari, CK; Raza, SA, 1998
)
2.46
"Hydralazine has been widely used to reduce tumor blood flow in mice. "( Comparative effects of hydralazine on perfusion of KHT tumor, kidney and liver and on renal function in mice.
Bleehen, NM; Honess, DJ, 1992
)
2.04
"Hydralazine has been reported to reduce blood perfusion in tumours, thereby increasing hypoxia and subsequently enhancing tumour sensitivity to certain drugs and hyperthermia. "( Hydralazine-induced changes in tissue perfusion and radiation response in a C3H mammary carcinoma and mouse normal tissues.
Fisker, RV; Horsman, MR; Overgaard, J, 1991
)
3.17
"Hydralazine has been shown to reduce tumour blood flow and to potentiate the cytotoxicity of melphalan and bioreductive agents in mice. "( The effects of single dose oral hydralazine on blood flow through human lung tumours.
Cronin, B; Flower, MA; Horwich, A; McCready, VR; Rowell, NP, 1990
)
2.01
"Hydralazine has been reported to potentiate tumor damage by hyperthermia as well as by hypoxic-cell-specific drugs through the reduction of tumor blood flow and pO2."( Effects of hydralazine on the blood flow in RIF-1 tumors and normal tissues of mice.
Lin, JC; Song, CW, 1990
)
1.39
"Hydralazine has been shown to increase minute ventilation, alveolar ventilation, and arterial partial pressure of oxygen (PaO2) after short-term administration in patients with chronic obstructive pulmonary disease and pulmonary hypertension. "( Long-term effects of hydralazine on ventilation and blood gas values in patients with chronic obstructive pulmonary disease and pulmonary hypertension.
Corriveau, ML; Dolan, GF, 1987
)
2.03
"Hydralazine has been shown to increase minute ventilation (VE) in patients with chronic obstructive pulmonary disease and pulmonary hypertension. "( Effects of hydralazine on mouth occlusion pressure and ventilatory response to hypercapnia in patients with chronic obstructive pulmonary disease and pulmonary hypertension.
Corriveau, ML; Dolan, GF; Shepard, JW, 1987
)
2.11
"Hydralazine has been employed as a test drug, but because of its long duration of action there is a risk of sustained systemic arterial hypotension in patients with a fixed pulmonary vascular resistance."( A comparison of the acute hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension.
Cato, AE; Frosolono, MF; Groves, BM; Reeves, JT; Rubin, LJ, 1985
)
1.23

Actions

Hydralazine can cause severe AKI resulting in CKD or death. Hydralazine to lower the diastolic blood pressure somewhat prevented intracranial hemorrhage. Dihydralazine may produce headache.

ExcerptReferenceRelevance
"Hydralazine can cause severe AKI resulting in CKD or death."( Hydralazine-associated adverse events: a report of two cases of hydralazine-induced ANCA vasculitis.
Asif, A; Costanzo, EJ; Dounis, H; Haj, RA; Patel, M; Seyedali, S; Zuckerman, R,
)
2.3
"Hydralazine could not inhibit this aggravation (GC-A-KO-Ang II-Hydralazine 13.5, 11.3 %)."( Aggravated renal tubular damage and interstitial fibrosis in mice lacking guanylyl cyclase-A (GC-A), a receptor for atrial and B-type natriuretic peptides.
Horio, T; Kangawa, K; Kawano, Y; Kishimoto, I; Kuwabara, A; Otani, K; Tokudome, T; Yoshihara, F, 2015
)
1.14
"Hydralazine was found to increase blood sugar level in intact rats when administered i.p."( Hyperglycemic effect of hydralazine in rats.
Hara, S; Kitagawa, H; Satoh, T; Takashima, M, 1980
)
1.29
"Dihydralazine may produce headache."( [Antihypertensive vasodilators].
Plouin, PF, 1983
)
0.82
"Hydralazine appeared to increase cardiac output and stroke volume by reducing systemic resistance."( Comparative actions of hydralazine, nifedipine and amrinone in primary pulmonary hypertension.
Ganz, R; Levy, PS; Rich, S, 1983
)
1.3
"Hydralazine did not cause a significant change in pulmonary arterial resistance or pressure in any group but produced a significant reduction in systemic resistance, which correlated with plasma concentration, and a significant increase in pulmonary blood flow index in all groups."( Haemodynamic response to intravenous hydralazine in patients with pulmonary hypertension.
Choo, MH; McGoon, MD; Moyer, TP; Reeder, GS; Seward, JB; Vlietstra, RE, 1983
)
1.26
"Hydralazine to lower the diastolic blood pressure somewhat, when it was 110 mm Hg or higher, prevented intracranial hemorrhage."( The Parkland Memorial Hospital protocol for treatment of eclampsia: evaluation of 245 cases.
Cunningham, FG; Pritchard, JA; Pritchard, SA, 1984
)
0.99
"The hydralazine-stimulated increase in PRA was also inhibited 75% (P less than 0.001) by indomethacin whereas noradrenaline and adrenaline concentrations were not significantly reduced."( Effect of indomethacin on hydralazine-induced renin and catecholamine release in the conscious rabbit.
Campbell, WB; Graham, RM; Jackson, EK; Loisel, DP; Pettinger, WA, 1980
)
1.04
"Hydralazine did not increase arterial oxygen tension (0.10 greater than p greater than 0.05), but exercise did (p less than 0.02)."( Arterial oxygenation and arterial oxygen transport in chronic myocardial failure at rest, during exercise and after hydralazine treatment.
Brown, HV; Rubin, SA; Swan, HJ, 1982
)
1.2
"Hydralazine prevented the increase of arterial pressure and the decrease of stress developed to NA by the aortic strips from both SHR and DOCA/salt rats."( Hydralazine prevents changes in the contractile response of aortic but not portal vein strips in hypertensive rats.
Pang, CC; Sutter, MC, 1980
)
2.43
"Hydralazine can also cause a systemic vasculitis with a pauci-immune rapidly progressive glomerulonephritis, which is associated with autoantibodies directed against components of the neutrophil cytoplasm."( Antigen specificity in hydralazine associated ANCA positive systemic vasculitis.
Lockwood, CM; Short, AK, 1995
)
1.32
"Hydralazine, which may cause tumour hypoxia and lower pHi as well as pHe, caused cytotoxity when given alone by chronic infusion, and enhanced the cytotoxicity due to nigericin."( The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects.
Tannock, IF; Yamagata, M, 1996
)
1.02
"With hydralazine, the increase in cardiac output without change in left ventricular filling pressure or pulmonary vascular resistance suggests minimal effect on preload but significant reduction in afterload."( Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure.
Conti, CR; Iacona, M; Mehta, J; Pepine, CJ, 1979
)
0.96
"Hydralazine failed to inhibit responses to any of the agonists tested in the fetal and maternal arteries."( Effects of vasodilators on isolated human uteroplacental arteries.
Allen, J; Forman, A; Maigaard, S; Skajaa, K, 1991
)
1
"Hydralazine tended to lower LV MCVR per 100 g in both strains despite its tendency to increase ventricular mass."( Role of lowering arterial pressure on maximal coronary flow with and without regression of cardiac hypertrophy.
Canby, CA; Tomanek, RJ, 1989
)
1
"Hydralazine does not inhibit vascular reactivity by a PG12 dependent mechanism although it stimulates prostaglandin biosynthesis."( Hydralazine inhibits vascular reactivity by a mechanism independent of vascular prostaglandin biosynthesis: role of thromboxane synthetase in blocking hydralazine actions.
Ally, AI; Horrobin, DF, 1986
)
2.44

Treatment

Dihydralazine treatment which lowered blood pressure in young rats from the Lyon Hypertensive Strain (LHS) did not change phenylethanolamine-N-methyltransferase (PNMT) activity, but decreased tyrosine hydroxylase and dopamine-beta-hydroxyl enzyme activities in the C2 medullary region. Hydralazine increased the mRNAs for both alpha and beta subunits of PH by three- to fourfold.

ExcerptReferenceRelevance
"Hydralazine pretreatment reversed DE-induced TF, tPA, TNF-α, and MMP-2 expression but not eNOS, RAGE, and HMGB-1."( Diesel exhaust induced pulmonary and cardiovascular impairment: the role of hypertension intervention.
Andrews, D; Bass, V; Gilmour, MI; King, C; Kodavanti, UP; Krantz, QT; Ledbetter, AD; Nyska, A; Richards, JE; Schladweiler, MC; Thomas, RF, 2013
)
1.11
"Hydralazine treatment further resulted in the accumulation of reactive oxygen species, whereas a superoxide dismutase mimetic inhibited hydralazine-induced cell death."( The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells.
Campillo-Davo, D; Lucendo, E; Martínez-Aguilar, R; Ruiz-Magaña, MJ; Ruiz-Ruiz, C; Schulze-Osthoff, K, 2016
)
1.46
"Hydralazine treatment significantly blocked the development of mesangiolysis and microaneurysms, whereas tubulointerstitial injury was not prevented in these mice."( Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice.
Atkinson, MA; Campbell-Thompson, M; Connor, T; Croker, BP; Grant, MB; Hauswirth, WW; Heinig, M; Kosugi, T; Li, Q; Nakagawa, T; Nakayama, T; Segal, MS; Yuzawa, Y; Zhang, L, 2009
)
1.07
"Hydralazine treatment attenuates cardiac fibrosis in response to angiotensin II."( Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent.
Bian, Y; Cheng, J; Du, J; Jia, L; Li, H; Li, Y; Qi, G; Xiao, C, 2011
)
1.09
"Hydralazine treatment markedly reduced (99m)Tc-MIBI and (201)Tl accumulation in LS180 xenografts; moreover, intratumoural pO(2) decreased from 14.5 +/- 6.6 mmHg to 7.6 +/- 6.2 mmHg."( Hypoxia-induced alteration of tracer accumulation in cultured cancer cells and xenografts in mice: implications for pre-therapeutic prediction of treatment outcomes with (99m)Tc-sestamibi, (201)Tl chloride and (99m)Tc-HL91.
Bai, J; Bunko, H; Kinuya, S; Li, XF; Michigishi, T; Shuke, N; Takayama, T; Tonami, N; Watanabe, N; Yokoyama, K, 2002
)
1.04
"Hydralazine treatment in obese animals attenuated obesity-related renin-angiotensin system (RAS) activation. "( Hydralazine as antihypertensive therapy in obesity-related hypertension.
Carroll, JF; Cohen, JS; King, JW, 2004
)
3.21
"Hydralazine treatment in obese rabbits did not exacerbate obesity-related cardiovascular and hormonal alterations. "( Hydralazine as antihypertensive therapy in obesity-related hypertension.
Carroll, JF; Cohen, JS; King, JW, 2004
)
3.21
"Hydralazine-treated animals had lower body fat (15.7 +/- 1.1 and 21.8 +/- 1.0%, respectively) and higher body water (59.8 +/- 0.8 and 55.4 +/- 0.6%, respectively) compared with controls. "( Hydralazine treatment alters body composition in the rabbit model of obesity.
Carroll, JF; Cohen, JS; King, JW, 2004
)
3.21
"Hydralazine treatment consisted of 6 mg/kg/day and 10 to 14 mg/kg/day for LH and OH, respectively."( Loss of diurnal rhythms of blood pressure and heart rate caused by high-fat feeding.
Carroll, JF; Strange, T; Thaden, JJ; Wright, AM, 2005
)
1.05
"Hydralazine, a well-known treatment for hypertension, has been reported to react with acrolein, forming hydrazone in cell-free systems."( Hydralazine rescues PC12 cells from acrolein-mediated death.
Borgens, RB; Liu-Snyder, P; Shi, R, 2006
)
2.5
"Hydralazine-treated SHR had normalized blood pressure but unaltered low ICP response."( Increased intracavernosal pressure response in hypertensive rats after chronic hemin treatment.
Shamloul, R; Wang, R, 2006
)
1.06
"Hydralazine treatment (4-5 weeks) prevented the development of hypertension in DOCA-salt rats and reduced blood pressure of SHRs to normotensive levels."( Sustained hypertension increases the density of AMPA receptor subunit, GluR1, in baroreceptive regions of the nucleus tractus solitarii of the rat.
Aicher, SA; Andresen, MC; Bailey, TW; Hermes, SM; Lynch, PJ; McKee, BL; Mitchell, JL; Silverman, MB, 2008
)
1.07
"Hydralazine treatment increased blood cAMP level, leading to the hyperglycemia, because pretreatment with phentolamine partially blocked the hydralazine-induced hyperglycemia."( Hyperglycemic effect of hydralazine in rats.
Hara, S; Kitagawa, H; Satoh, T; Takashima, M, 1980
)
1.29
"In hydralazine-treated rats, the catecholamine levels were unchanged in the brain stem and heart."( Central and peripheral indices of sympathetic activity after blood pressure lowering with enalapril (MK-421) or hydralazine in normotensive rats.
Bresnahan, M; Gavras, H; Kohlmann, O,
)
0.86
"Dihydralazine treatment increased vascular mesenteric compliance, as shown by a significant decrease in the stiffness of the vessels (-27%), and induced slight reductions in contractility (-12%) and in wall to lumen (W/L) ratio (-15%)."( Compared myocardial and vascular effects of captopril and dihydralazine during hypertension development in spontaneously hypertensive rats.
Freslon, JL; Giudicelli, JF, 1983
)
1.07
"Both hydralazine pretreatment (1 mg/kg i.v., 1 hr before testing) and partial aortic occlusion during testing decreased femoral perfusion pressure without increasing vasodilator responses of the femoral arterial bed to adenosine, nitroglycerin, acetylcholine or isoproterenol."( Effect of reserpine pretreatment on in vivo femoral arterial responses to vasodilator agents.
Cauvin, CA; Devia, CJ; Kirkendol, PL, 1981
)
0.72
"Hydralazine treatment did not alter cell-mediated immune responses."( Prospective study of immunologic effects of hydralazine in hypertensive patients.
Adams, LE; Foad, B; Hess, EV; Litwin, A; Loggie, JH; Zimmer, H, 1981
)
1.25
"Hydralazine treatment did not alter cell-mediated immune responses and hydralazine antibodies were not detected."( Immunologic effects of hydralazine in hypertensive patients.
Adams, LE; Hess, EV; Litwin, A; Zimmer, H, 1981
)
1.29
"Hydralazine-treated rats had a significantly lower systolic pressure after 1 week which remained lower for the remainder of the treatment period."( Mechanical and biochemical alterations of aorta induced by hydralazine hypotension.
Allen, JC; Bowers, RL; Seidel, CL, 1980
)
1.23
"Hydralazine-treated WKY and SHR had significantly reduced tension and maximum rates of tension development and relaxation; passive length-tension characteristics were not altered."( Hydralazine: effect on contraction mechanics of WKY and SHR rat heart muscle.
Michael, LH; Seidel, CL,
)
2.3
"3. Hydralazine treatment may result in the appearance of dopamine as a significant co-transmitter in noradrenergic nerves, and this may contribute to the antihypertensive effect of hydralazine."( Inhibition by hydralazine of the conversion of dopamine to noradrenaline in rat atria in vitro and in vivo.
Majewski, H; Rand, MJ; Songkittiguna, P,
)
1.01
"Hydralazine-treated STZ-diabetic rats had serum triglyceride and cholesterol levels that did not differ from controls."( Effect of hydralazine on myocardial plasma membrane fatty acid binding protein (PM-FABP) during diabetes mellitus.
Heyliger, CE; Powell, DM; Skau, KA, 1995
)
1.41
"Hydralazine treatment and sodium deprivation did not significantly modify the pressure-independence of renin release by LH rat kidneys."( Pressure control of renal renin release in Lyon hypertensive rats.
Bertolino, S; Medeiros, IA; Sassard, J; Zhang, BL, 1994
)
1.01
"Hydralazine treatment, with or without ascorbate, severely decreased the alpha 1(I) collagen mRNAs in fibroblasts from both AT750 and the normal donor; total collagen synthesis was similarly reduced."( The mRNA and the activity of lysyl hydroxylase are up-regulated by the administration of ascorbate and hydralazine to human skin fibroblasts from a patient with Ehlers-Danlos syndrome type VI.
Marshall, MK; Murad, S; Pinnell, SR; Walker, LC; Yeowell, HN, 1995
)
1.23
"Hydralazine treatment did not alter the isoproterenol-induced chronotropic effect in right atrium."( Effects of hydralazine on cardiac responsiveness to adrenergic agonists in streptozotocin-induced diabetic rats.
Goyal, RK, 1993
)
1.4
"In hydralazine-treated SHR and captopril-treated SHR, the pressure-rate product and extent of recovery of the coronary flow during reperfusion following 30 min of ischemia were higher than those in control SHR, but this difference was significant only in captopril-treated SHR."( Effect of regression of cardiac hypertrophy on ischemic myocardial damage in spontaneously hypertensive rats.
Abe, M; Haneda, T; Okamoto, K, 1993
)
0.8
"Hydralazine-treated SHRs had a collagen I:III ratio of 10.07 +/- 0.39, which is similar to the ratio in untreated SHRs."( Alteration of cardiac collagen phenotypes in hypertensive hypertrophy: role of blood pressure.
Mukherjee, D; Sen, S, 1993
)
1.01
"3. Hydralazine treatment effectively lowered blood pressure to the same level of sham-operated and WKY rats."( Effect of an antihypertensive drug on brain angiotensin II levels in renal and spontaneously hypertensive rats.
Aoki, M; Higaki, J; Moriguchi, A; Morishita, R; Nakamura, Y; Rakugi, H; Tomita, N; Tomita, S; Yamada, K; Yu, H, 1995
)
0.81
"Hydralazine-treated SHR had increased characteristic impedance (P = .0011) and a persistently low ratio of the reflected-wave transit time to left ventricular ejection time (P < .001), which contributed to early and late systolic loading, respectively, of the left ventricle."( Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats.
Finn, PV; Mitchell, GF; Pfeffer, JM; Pfeffer, MA, 1996
)
1.02
"Hydralazine treatment normalized blood pressure in ANG II-infused rats."( Mechanisms contributing to angiotensin II regulation of body weight.
Cassis, LA; Fettinger, MJ; Lodder, RA; Marshall, DE; Rosenbluth, B, 1998
)
1.02
"Hydralazine treatment also inhibited development of EDCF."( L-Arginine improves endothelial function in renal artery of hypertensive Dahl rats.
Abe, Y; Chen, QH; Kosaka, H; Tian, RX; Yamamoto, A; Yoneyama, H; Zhang, L; Zhou, MS, 2001
)
1.03
"Hydralazine treatment for 2 weeks was less effective on vascular regression with a mean yield of -7.3% +/- 2.9% (p <0.05) and it did not alter left ventricle hypertrophy compared with controls (3.7% +/- 5.0%)."( Antihypertensive drugs induce structural remodeling of the penile vasculature.
Adams, MA; Hale, TM; Heaton, JP; Okabe, H, 2001
)
1.03
"Hydralazine-treated, normotensive male apoE/eNOS DKO mice developed increased aortic lesion areas (30.0+/-2.8%, n=11) compared with male apoE KO mice (14.6+/-0.8%, n=7)."( Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice.
Astern, J; Chen, J; Gyurko, R; Huang, PL; Kuhlencordt, PJ, 2001
)
1.03
"Hydralazine treatment of young SHR partially prevented the increase of both alkaline phosphatase activity and blood pressure that develops with age."( Relationship between blood pressure of spontaneously hypertensive rats and alterations in membrane properties of mesenteric arteries.
Daniel, EE; Janis, RA; Wei, JW, 1977
)
0.98
"Dihydralazine treatment which lowered blood pressure in young rats from the Lyon Hypertensive Strain (LHS), did not change phenylethanolamine-N-methyltransferase (PNMT) activity, but decreased tyrosine hydroxylase and dopamine-beta-hydroxylase activities in the C2 medullary region. "( Dihydralazine and catecholamine-synthesizing enzymes in spontaneous hypertension.
Denoroy, L; Renaud, B; Sacquet, J; Sassard, J; Vincent, M, 1979
)
1.7
"Hydralazine treatment increased the mRNAs for both alpha and beta subunits of PH by three- to fourfold."( Hydralazine differentially increases mRNAs for the alpha and beta subunits of prolyl 4-hydroxylase whereas it decreases pro alpha 1(I) collagen mRNAs in human skin fibroblasts.
Murad, S; Pinnell, SR; Yeowell, HN, 1991
)
2.45
"Hydralazine-treated patients also had significant decreases in LV end-diastolic and end-systolic volume indexes, and a significant increase in ejection fraction."( Effects of long-term vasodilator therapy on electrocardiographic abnormalities in chronic aortic regurgitation.
Bristow, JD; Cheitlin, M; Greenberg, B; Jacobson, N; Massie, B; Perlmutter, N; Siemienczuk, D; Szlachcic, J; Wilson, R, 1991
)
1
"Hydralazine treatment resulted in a threefold increase in tropoelastin mRNA levels in both the SHR and the WKY animals (P less than 0.01)."( Changes in aortic levels of tropoelastin mRNA following treatment of rats with the antihypertensive drugs captopril and hydralazine.
Alden, SM; Boyd, CD; Deak, SB; Mackenzie, JW; Pierce, RA; Tozzi, CA, 1991
)
1.21
"Hydralazine treatment, which prevented the development of hypertension, attenuated the increased 3H overflow evoked by PNS in SHR."( Effect of chronically administered hydralazine on altered adrenergic neurotransmission mediated by presynaptic alpha- and beta-adrenoceptors in spontaneously hypertensive rats.
Kato, H; Mochizuki, S; Takata, Y, 1990
)
1.28
"Hydralazine treatment was found to reduce the response in a dose-dependent manner."( Effects of calcium channel blockers and hydralazine on epinephrine-induced stimulation of glucose output from primary cultured rat hepatocytes.
Ogihara, M; Sunaga, K, 1990
)
1.27
"Hydralazine treatment normalized blood pressure in SHR but did not cause regression of cardiac hypertrophy (heart weight to body weight ratio of SHR + hydralazine 4.33 +/- 0.098 vs."( Vascular remodeling and improvement of coronary reserve after hydralazine treatment in spontaneously hypertensive rats.
Anderson, PG; Bishop, SP; Digerness, SB, 1989
)
1.24
"Hydralazine treatment prevented hypertension in DOCA + HYD but did not prevent development of cardiac hypertrophy (heart weight/body weight of DOCA + HYD 3.99 +/- 0.1 vs."( Coronary vascular function and morphology in hydralazine treated DOCA salt rats.
Anderson, PG; Bishop, SP; Digerness, SB, 1988
)
1.26
"Hydralazine treatment successfully prevented all these alterations."( Effects of hydralazine on streptozotocin-induced diabetic rats: prevention of hyperlipidemia and improvement in cardiac function.
Goyal, RK; McNeill, JH; Rodrigues, B, 1986
)
1.38
"Pre-treatment with hydralazine was shown to inhibit both mitochondrial fission and mitochondrial membrane depolarisation induced by oxidative stress in HeLa cells. "( Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission.
Chinda, K; Costa, JRSD; Crespo-Avilan, GE; Hausenloy, DJ; Hernandez-Resendiz, S; Holien, JK; Kalkhoran, SB; Ketteler, R; Kriston-Vizi, J; Lees, JG; Lim, SY; Ling, NXY; Riquelme, JA; Rosdah, AA; Samangouei, P; Yap, EP; Yellon, DM, 2022
)
2.49
"Treatment with hydralazine at hypotensive dose for 12 weeks also failed to affect the proteinuria in 5 of 6 nephrectomized CKD rats."( Involvement of renal sympathetic nerve overactivation in the progression of chronic kidney disease in rats.
Ayajiki, K; Funai, A; Kobuchi, S; Matsumura, Y; Ohkita, M; Suzuki, R; Tanaka, R; Tsutsui, H; Yazawa, M, 2014
)
0.74
"Treatment with hydralazine reversed gemcitabine resistance and led to hENT1 and dCK gene reactivation in a DNA promoter methylation-independent manner."( DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells.
Candelaria, M; Chavez-Blanco, A; de la Cruz-Hernandez, E; Diaz-Chavez, J; Dominguez, G; Duenas-Gonzalez, A; Gonzalez-Fierro, A; Perez-Cardenas, E; Soto-Reyes, E; Taja-Chayeb, L; Trejo-Becerril, C; Trujillo, JE, 2012
)
0.95
"Pretreatment with hydralazine caused prolongation of hypnosis induced by hexobarbital (80 mg/kg, i.p.) or intracerebroventricular injection of phenobarbital (1 mg/rat). "( Induction of hypersensitivity of brain by hydralazine treatment in rats.
Hara, S; Kitagawa, H; Satoh, T, 1981
)
0.86
"Treatment with hydralazine did not reduce infarct size [59.4(4.3)%]."( Effect of bimakalim (EMD 52692), an opener of ATP sensitive potassium channels, on infarct size, coronary blood flow, regional wall function, and oxygen consumption in swine.
Becker, KH; Häusler, G; Lues, I; Rohmann, S; Schelling, P; Soei, LK; Verdouw, PD; Weygandt, H, 1994
)
0.63
"Treatment with hydralazine had no effect on the morphometric parameters evaluated, whereas isradipine administration significantly reduced the thickening of both the wall and the tunica media of the aorta, and reduced the wall: lumen ratio."( Influence of isradipine treatment on the morphology of the aorta in spontaneously hypertensive rats.
Abbate, F; Amenta, F; Ciriaco, E; Ferrante, F; Laurà, R, 1994
)
0.63
"Treatment with hydralazine significantly lowered arterial pressure in SHR and WKY rats, but did not alter the enhanced contraction to phenylephrine or the enhanced relaxation to acetylcholine and nitroprusside in coronary arteris from SHR."( Characterization of endothelium-dependent vasodilation and vasoconstriction in coronary arteries from spontaneously hypertensive rats.
Fuchs, LC; Johnson, AK; Lamping, KG; Nuno, D, 1996
)
0.63
"Treatment with hydralazine in rabbits not receiving nitroglycerin significantly decreased .O2- production in intact rabbit aorta and increased sensitivity to nitroglycerin."( Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug.
Berrington, WR; Freeman, BA; Harrison, DG; Kurz, S; Münzel, T; Rajagopalan, S; Thoenes, M; Thompson, JA, 1996
)
2.08
"Treatment with hydralazine had little or no effect on LVH and cardiac fibrosis and did not modify inducibility of ventricular arrhythmias by PES."( Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine.
El Salibi, E; Nguyen, T; Rouleau, JL, 1998
)
0.84
"Untreated and hydralazine-treated dTGR showed increased nuclear factor (NF)-kappaB and AP-1 expression in the kidney and heart; the p65 NF-kappaB subunit was increased in the endothelium, vascular smooth muscles cells, infiltrating cells, glomeruli, and tubules."( Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage.
Breu, V; Dechend, R; Ganten, D; Genersch, E; Haller, H; Löffler, BM; Luft, FC; Mervaala, EM; Muller, DN; Park, JK; Schmidt, F; Schneider, W, 2000
)
0.65
"Treatment with hydralazine decreased blood pressure in a similar way as trandolapril but did not affect either LV weight or LV Ang II."( Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy.
Higaki, J; Higashimori, K; Mikami, H; Nagano, M; Nagano, N; Nakamura, F; Ogihara, T, 1992
)
0.62
"Treatment with hydralazine was effective in preventing increases in elastin (128 +/- 14 microns2) and in attenuating increases in smooth muscle (1,008 +/- 18 microns2)."( Effects of antihypertensive treatment on composition of cerebral arterioles.
Baumbach, GL; Ghoneim, S; Hajdu, MA; Heistad, DD, 1991
)
0.62
"Treatment with hydralazine did not affect left ventricular weight and caused a small increase in the weight of the right ventricle."( Effects of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats.
Leenen, FH; Tsoporis, J, 1988
)
0.61
"Treatment with hydralazine-nitrate produced a 28% reduction in mortality compared with that in patients receiving placebo (95% confidence interval, 3% to 46%), whereas prazosin exerted no apparent beneficial effect."( Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate.
Archibald, DG; Cohn, JN; Dunkman, WB; Flohr, KH; Franciosa, JA; Francis, GS; Harston, WE; Jacobs, W; Tristani, FE; Ziesche, S, 1987
)
0.81
"Pretreatment with hydralazine (0.3-10.0 mg/kg i.v.) resulted in a dose dependent reduction in elevated plasma creatinine levels 24 hr after a 60 min ischemic episode, indicating a protective effect on post-ischemic renal function."( Protective effects of hydralazine in a renal ischemia model in the rat.
Agnello, A; Hirkaler, G; Rosenberger, L; Urbano, S; Vergona, RA, 1987
)
0.91

Toxicity

Intravenous (IV) hydralazine, enalapril and labetalol are oftentimes used without indication for the treatment of asymptomatic hypertension in the hospital setting. These drugs have been shown to have substantial adverse effects that are associated with increased morbidity and mortality.

ExcerptReferenceRelevance
"Antihypertensive agents have been associated with adverse reactions that, if unrecognized by health practitioners, may have devastating consequences."( Fatal hepatotoxicity induced by hydralazine or labetalol.
Stumpf, JL, 1991
)
0.56
" Our studies with one such agent, the vasodilator hydralazine, have clearly demonstrated that it can increase the tumor cytotoxicity of drugs which are known to be more toxic under hypoxic conditions."( Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs.
Acker, B; Chaplin, DJ; Olive, PL, 1989
)
0.53
" A beta-blocker (80 mg/day of nadolol) was added only for patients who had beta-blocker-responsive adverse effects that could not be controlled otherwise."( Comparative efficacy and safety of immediate-release and controlled-release hydralazine in black hypertensive patients.
Adir, J; Curry, CL; Janda, SM; Poku, CD; Rotenberg, KS; Taylor, RE, 1987
)
0.5
" Such reduced tumor oxygenation would increase the cytotoxic effects of RSU-1069 which is known to be more toxic to cells at reduced oxygen levels."( The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain.
Acker, B; Chaplin, DJ, 1987
)
0.63
" Other reported effects are toxic confusional states and psychotic reactions."( Psychiatric side effects of antihypertensive drugs other than reserpine.
Fleminger, R; Paykel, ES; Watson, JP, 1982
)
0.26
" a) In mice, a single ip administration of the LD50 of the three drugs caused a small but statistically significant increase over controls in DNA elution rate, ie, a modest amount of DNA fragmentation, in three of the four organs (liver, lung, kidney, and spleen) tested, DNA damage being absent in lung for hydralazine and endralazine and in liver for dihydralazine."( In vivo and in vitro genotoxicity of three antihypertensive hydrazine derivatives (hydralazine, dihydralazine, and endralazine).
Bennicelli, C; Brambilla, G; Cajelli, E; Camoirano, A; Cavanna, M; de Flora, S; Faggin, P; Sciabà, L; Zanacchi, P, 1982
)
0.66
" It has been shown that a vasoactive role may be partially responsible for the toxic effects of CN."( The effects of EDRF/NO releasers or calcium ionophore A23187 on cyanide toxicity in mice.
Baskin, SI; Lempka, JC; Nealley, EW, 1996
)
0.29
"Acrolein is a highly toxic aldehyde involved in a number of diseases as well as drug-induced toxicities."( Protein adduct-trapping by hydrazinophthalazine drugs: mechanisms of cytoprotection against acrolein-mediated toxicity.
Burcham, PC; Fontaine, FR; Kaminskas, LM; Petersen, DR; Pyke, SM, 2004
)
0.32
" The most common adverse events, headache (34%) and dizziness (16%), were less than in patients taking ID/H in A-HeFT, with only 6% discontinuations for adverse events."( Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial).
Archambault, WT; Braman, VM; Franciosa, JA; Ghali, JK; Sabolinski, ML; Worcel, M; Yancy, CW, 2007
)
0.56
" Because little information is available concerning the extent of intermolecular protein cross-linking during acrolein toxicity in cells, we used an antibody against a known target for toxic carbonyls, the chaperone protein Hsp90, to detect the formation of high-mass protein complexes in acrolein-exposed A549 cells."( Intermolecular protein cross-linking during acrolein toxicity: efficacy of carbonyl scavengers as inhibitors of heat shock protein-90 cross-linking in A549 cells.
Burcham, PC; Raso, A; Tan, D; Thompson, C, 2007
)
0.34
" Demographic data and data on adverse effects (AE), BP, and heart rate (HR) prior to and after each first dose were collected."( The efficacy and safety of intravenous hydralazine for the treatment of hypertension in the hospitalized child.
Chessman, K; Egan, B; Hailpern, SM; Jones, J; Ostrye, J; Shatat, IF, 2014
)
0.67
"Occurrence of adverse events and relative hypotensive events during all episodes treated with the protocol, and efficacy of attaining target blood pressure for all episodes with protocol adherence and for initial episode experienced by each patient."( A retrospective review of safety using a nursing driven protocol for autonomic dysreflexia in patients with spinal cord injuries.
Bunnell, AE; Burns, SP; James, JJ; Solinsky, R; Svircev, JN, 2016
)
0.43
" Twenty-three total adverse events occurred (5."( A retrospective review of safety using a nursing driven protocol for autonomic dysreflexia in patients with spinal cord injuries.
Bunnell, AE; Burns, SP; James, JJ; Solinsky, R; Svircev, JN, 2016
)
0.43
"This inpatient nursing driven-protocol for treating autonomic dysreflexia utilizing conservative measures, nitroglycerin paste and oral hydralazine achieved target blood pressure with a high success rate and a low incidence of adverse events."( A retrospective review of safety using a nursing driven protocol for autonomic dysreflexia in patients with spinal cord injuries.
Bunnell, AE; Burns, SP; James, JJ; Solinsky, R; Svircev, JN, 2016
)
0.64
" Alcohol consumption and cigarette smoking are known risk factors for HIV hepatotoxicity, and both are significant sources of acrolein, a highly reactive and toxic aldehyde."( Acrolein enhances epigenetic modifications, FasL expression and hepatocyte toxicity induced by anti-HIV drug Zidovudine.
Barker, DF; Barve, SS; Chen, WY; Donde, H; Ghare, SS; Gobejishvilli, L; Joshi-Barve, S; McClain, CJ, 2016
)
0.43
"Intravenous (IV) hydralazine, enalapril and labetalol are oftentimes used without indication for the treatment of asymptomatic hypertension in the hospital setting and have been shown to have substantial adverse effects that are associated with increased morbidity and mortality, as well as longer length of stay."( Improving the use of intravenous antihypertensive medications in the hospital setting: a quality improvement initiative for patient safety.
Chams, N; Gjeka, R; Kumar, S; Peterson, D; Ross, I; Salman, A; Salman, J; Tegeltija, V, 2019
)
0.85
" Full-text, English-language articles describing IV labetalol and/or hydralazine use for non-emergent HTN in an inpatient setting that focused on clinical outcomes (ie vitals, adverse effects, healthcare utilisation) were included."( Safety and efficacy of intravenous hydralazine and labetalol for the treatment of asymptomatic hypertension in hospitalised patients: A systematic review.
Cawoski, JR; Covvey, JR; DeBiasio, KA; Donnachie, SW; Guarascio, AJ; Montepara, CA; Nemecek, BD; Timanus, EA; Zimmerman, DE, 2021
)
1.13
" The included studies presented a variety of outcomes, but several trends were identified, including reduction in average blood pressure in eight (80%) studies, a risk of adverse effects in six (60%) and increased length of stay in one (10%)."( Safety and efficacy of intravenous hydralazine and labetalol for the treatment of asymptomatic hypertension in hospitalised patients: A systematic review.
Cawoski, JR; Covvey, JR; DeBiasio, KA; Donnachie, SW; Guarascio, AJ; Montepara, CA; Nemecek, BD; Timanus, EA; Zimmerman, DE, 2021
)
0.9
" Previous evidence suggests that management with one-time doses of intravenous (IV) antihypertensives may increase adverse events."( Reduction of Intravenous Antihypertensives through Clinical Decision Support in a Large Safety Net System.
Alaiev, D; Chandra, K; Cho, HJ; Garcia, M; Krouss, M; Manchego, PA; Shin, D; Talledo, J; Tsega, S; Zaurova, M,
)
0.13

Pharmacokinetics

The influence of various disease states, other than hypertension, on the pharmacokinetic behaviour of hydralazine is not completely known. Metoprolol is affected by hydralazines, the AUC and Cmax being significantly increased.

ExcerptReferenceRelevance
" Pharmacokinetic variables have been determined that allow: (1) derivation of the loading dose necessary to achieve rapid control of blood pressure with propranolol hydrochloride, guanethidine, minoxidil and clonidine hydrochloride; (2) reduced frequency of dosing with methyldopa, hydralazine hydrochloride, prazosin hydrochloride, propranolol and clonidine; and (3) alteration of propranolol and hydralazine dosage based on physiologic factors (e."( Using pharmacokinetics in drug therapy. V: Contributions to developing dosage regimens for antihypertensive drugs.
Schumacher, GE, 1979
)
0.44
" Lack of specific assay techniques for its measurement have delayed elucidation of its pharmacokinetic profile."( Pharmacokinetics of hydralazine, apparent hydralazine and hydralazine pyruvic acid hydrazone in humans.
Haegele, KD; Ludden, TM; McNay, JL; Shepherd, AM; Talseth, T, 1979
)
0.58
" Pharmacokinetic analysis showed that AUCoral/dose (5552 to 13218 mg-min/ml) and F (0."( Hydralazine pharmacokinetics and interaction with food: an evaluation of the dog as an animal model.
Coutts, RT; Semple, HA; Tam, YK, 1990
)
1.72
" A five-compartment pharmacokinetic model was presented to elucidate the disposition of HAH and two products, HP and HPH."( Pharmacokinetics and biotransformation of hydralazine acetone hydrazone, a metabolite of hydralazine, in the rat.
Ito, Y; Iwaki, M; Ogiso, T, 1989
)
0.54
" Pharmacokinetic data indicate hydralazine is absorbed well from the gastrointestinal tract, and has an extensive and complex metabolism depending on acetylator status: slow acetylators undergo primary oxidative metabolism, while rapid acetylators are acetylated."( Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure.
Crawford, MH; Mulrow, JP, 1989
)
0.82
" Nisoldipine had the lowest maximum plasma concentration and the longest elimination half-life among the four 1,4-dihydropyridines, resulting in no significant difference in the area under the plasma concentration-time curve."( Comparative study on acute antihypertensive effects and pharmacokinetics of nisoldipine, nifedipine, nimodipine and nicardipine administered orally to conscious renal hypertensive dogs.
Kato, H; Takata, Y, 1986
)
0.27
" Metoprolol is affected by hydralazine, the AUC and Cmax being significantly increased."( The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: metoprolol, nadolol, and acebutolol.
Dean, S; Jack, DB; Kendall, MJ; Laugher, SJ; Tenneson, ME; Zaman, R,
)
0.79
"The influence of various disease states, other than hypertension, on the pharmacokinetic behaviour of hydralazine is not completely known."( Pharmacokinetics of oral hydralazine in chronic heart failure.
Hanson, A; Johansson, BW; Wåhlander, LA; Wernersson, B, 1983
)
0.78
" Additionally, physiological parameters considered to be relevant to the pharmacokinetic handling (absorption rate and splanchnic hemodynamics) were studied."( Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow.
Bourne, R; Constantinides, S; Corbett, H; Heinzow, B; McLean, AJ, 1984
)
0.57
"The possibility to apply impedance cardiography technique and individual statistical analysis based on Dixon's criterion to pharmacodynamic studies of single hydralazine ( apressine ), prazosine ( pratsiol ), endralazine ( mirethilan ), propranolol (obsidan) doses is discussed."( [Methodologic approach to individual evaluation of the pharmacodynamic effects of single doses of hydralazine, endralazine, prazosine and propranolol in hypertension patients].
Izotov, AI; Postol'nikov, SF; Vygodin, VA, 1984
)
0.68
" Following a 20-mg intravenous infusion, the elimination half-life (t 1/2 beta) and the apparent volume of distribution of H did not differ between the two groups."( Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.
Azarnoff, DL; Hosler, JP; Schroder, RL; Shen, DD, 1980
)
0.58
" By simultaneously monitoring the effects in various tissues, the pharmacokinetic effect of each drug in the entire body could be obtained."( Pharmacokinetic changes induced by vasomodulators in kidneys, livers, muscles, and implanted tumors in rats as measured by dynamic Gd-DTPA-enhanced MRI.
Lao, X; Nalcioglu, O; Roth, GM; Samoszuk, MK; Su, MY; Wang, Z, 1996
)
0.29
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" This clinical PK data might also be helpful in the development of a pharmacokinetic model of hydralazine."( A review on the clinical pharmacokinetics of hydralazine.
Alqahtani, F; Ashraf, W; Hussain, I; Imran, I; Khalid, S; Majeed, A; Rasool, MF; Rehman, AU; Saeed, H; Shahzad Qamar, A; Zamir, A, 2022
)
1.2

Compound-Compound Interactions

Hydralazine combined with nitrate did not significantly alter any electrophysiological variable. The effects of CA4P alone or in combination with the antihypertensive drug hydralazine (HDZ) on mean arterial.

ExcerptReferenceRelevance
"The effect of long-term treatment of hypertension with propranolol, alone or in combination with hydrochlorothiazide and/or dihydralazine, was investigated in 93 patients with various types of hypertension."( [Long-term treatment of arterial hypertension with propranolol. Combination with diuretics and dihydrazinophthalazine].
Ambrosio, G; Corgnati, A; Dal Palù, C; Palatini, P; Pessina, AC, 1978
)
0.46
"Changes in central haemodynamics, electrophysiological parameters, and induction of ventricular tachycardia during treatment with captopril, or hydralazine combined with nitrate, compared with a control period."( Comparative electrophysiological effects of captopril or hydralazine combined with nitrate in patients with left ventricular dysfunction and inducible ventricular tachycardia.
Bashir, Y; Camm, AJ; Gibson, S; O'Nunain, S; Paul, VE; Sneddon, JF; Ward, DE, 1992
)
0.73
" Hydralazine combined with nitrate did not significantly alter any electrophysiological variable."( Comparative electrophysiological effects of captopril or hydralazine combined with nitrate in patients with left ventricular dysfunction and inducible ventricular tachycardia.
Bashir, Y; Camm, AJ; Gibson, S; O'Nunain, S; Paul, VE; Sneddon, JF; Ward, DE, 1992
)
1.44
"Load manipulation by captopril but not hydralazine combined with nitrate prolonged ventricular refractoriness and repolarisation, possibly reflecting a combination of mechano-electrical effect with the restraining influence of ACE inhibitors on reflex sympathetic stimulation."( Comparative electrophysiological effects of captopril or hydralazine combined with nitrate in patients with left ventricular dysfunction and inducible ventricular tachycardia.
Bashir, Y; Camm, AJ; Gibson, S; O'Nunain, S; Paul, VE; Sneddon, JF; Ward, DE, 1992
)
0.8
"075 mg/kg) of felodipine in combination with the beta-blocker and diuretic."( Felodipine in combination with a beta-blocker and a diuretic in chronic treatment of patients with refractory primary hypertension.
Andersson, OK; Granérus, G; Hedner, T, 1987
)
0.27
" Sustained release propranolol 160 mg was given orally either alone or in combination with oral hydralazine 25 mg on separate occasions to six healthy volunteers."( Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions.
Byrne, AJ; Harrison, PM; Louis, W; McLean, AJ; McNeil, JJ; Tonkin, AM, 1984
)
0.71
"The optimal daily dose and dose regimen of a new drug combination (Pertenso), consisting of 10 mg bemetizide, 20 mg triamterene, 20 mg dihydralazine and 20 mg bupranolol were tested in 14 hypertensive outpatients (WHO I to III) in a single blind crossover trial."( [Treatment of hypertension with a drug combination, consisting of bemetizide, triamterene, dihydralazine and bupranolol (author's transl)].
Brandstetter, G; Gasser, RW; Skrabal, F, 1982
)
0.69
" This may be particularly important in cases in which hypotensive action is exerted by the agent used in combination with the calcium channel blocker."( Shuttle-box avoidance behavior of mice treated with nifedipine in combination with nicotine or physostigmine.
Battaglia, M; Sansone, M; Vetulani, J,
)
0.13
" Thus, hyperthermochemotherapy using CQ combined with HYD, seems to selectively attack a solid tumor."( Hydralazine combined with hyperthermia enhances the effects of carboquone.
Baba, H; Emi, Y; Kusumoto, T; Maehara, Y; Sugimachi, K; Takahashi, I; Yoshida, M,
)
1.57
"An electron-affinic compound, AK-2123, and the anti-hypertensive agent, hydralazine, were combined with radiation and hyperthermia for treatment of murine SCC-VII tumours."( The use of a hypoxic cell radiosensitizer AK-2123 gave no improvement in thermoradiotherapy combined with hydralazine.
Akagi, K; Hasegawa, T; Imamura, M; Kagiya, VT; Kozin, SV; Kozina, LV; Tanaka, Y,
)
0.58
" The aim of this study was to use a mouse model to investigate whether hypertension or its modification influenced the treatment efficacy of CA4P in combination with other therapies."( Combretastatin-induced hypertension and the consequences for its combination with other therapies.
Bohn, AB; Busk, M; Horsman, MR; Skals, M; Wang, T,
)
0.13
" The effects of CA4P alone or in combination with the antihypertensive drug hydralazine (HDZ) on mean arterial blood pressure (MABP), hematocrit (Hct) and hemoglobin concentration ([Hb]) were characterized in non-tumor-bearing animals."( Combretastatin-induced hypertension and the consequences for its combination with other therapies.
Bohn, AB; Busk, M; Horsman, MR; Skals, M; Wang, T,
)
0.36
" Hydralazine-valproate is safe when used alone or in combination with chemotherapy or chemoradiation."( Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
Cetina, L; Chavez-Blanco, A; Coronel, J; Dueñas-Gonzalez, A; González-Fierro, A; Taja-Chayeb, L, 2014
)
2.76

Bioavailability

The apparently modest effect on survival observed in V-HeFT II could be explained in part by the poor hydralazine bioavailability of the tablet preparation used in this trial.

ExcerptReferenceRelevance
"The influence of food on the bioavailability of hydralazine in noncoated and coated tablets was examined in 5 healthy males."( Enhancement of hydralazine bioavailability by food.
Danielson, K; Hanson, A; Melander, A; Rudell, B; Scherstén, B; Thulin, T; Wåhlin, E, 1977
)
0.87
"The bioavailability of orally administered hydralazine was assessed in 4 healthy subjects after separate administration of a single oral or intravenous dose (0."( Studies on hydralazine. III. Bioavailability of hydralazine in man.
Talseth, T, 1976
)
0.91
" In this study, 12 healthy male volunteers participated in a two-way crossover trial that was designed to test the bioavailability and release of drug from the sustained-release formulation both with and without concomitant ingestion of a solution of KCl."( Comparative bioavailability of a sustained-release ion-exchange hydralazine product with a potassium (cation) challenge.
Ludden, LK; Ludden, TM; Rotenberg, KS; Shepherd, AM; Woodworth, JR, 1992
)
0.52
" The bioavailability of hydralazine in the dog was decreased by 63% when the dose was given with a meal, which is comparable to some human data."( Hydralazine pharmacokinetics and interaction with food: an evaluation of the dog as an animal model.
Coutts, RT; Semple, HA; Tam, YK, 1990
)
2.03
" Although hydralazine had no effect on the bioavailability of enalapril, significantly increased bioavailability was observed with lisinopril."( Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine.
Drummer, OH; Froomes, P; McLean, AJ; McNeil, JJ; Smith, HJ, 1989
)
0.91
" Half-lives, clearances and bioavailability of the drug are not significantly altered in congestive heart failure compared with hypertensive patients."( Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure.
Crawford, MH; Mulrow, JP, 1989
)
0.53
"The concomitant administration of hydralazine with metoprolol or propranolol substantially increases the oral bioavailability of these beta-blockers, presumably via reduction of the first-pass effect."( Effect of hydralazine on the elimination of antipyrine in the rat.
Knowlton, PW; Svensson, CK; Ware, JA, 1987
)
0.95
"Several recent studies have shown that hydralazine and nitroglycerin may increase the apparent oral bioavailability of high-clearance drugs."( Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow.
Cumella, JC; Lalka, D; Middleton, E; Svensson, CK; Tronolone, M, 1985
)
0.93
" Our data indicate that hydralazine increases propranolol bioavailability by its hemodynamic actions rather than by inhibition of its metabolism."( Mechanism by which hydralazine increases propranolol bioavailability.
Schneck, DW; Vary, JE, 1984
)
0.9
"The influence of concomitant food intake on the bioavailability of hydralazine was studied in healthy volunteers following single-dose administrations in the fasting state and together with a standardized breakfast meal of 1840 kJ (440 kcal)."( Influence of food on the bioavailability of "real" and "apparent" hydralazine from conventional and slow-release preparations.
Hanson, A; Liedholm, H; Melander, A; Wåhlin-Boll, E, 1982
)
0.74
" Bioavailability of Bft was not altered following administration of the fixed combination."( Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine.
Mutschler, E; Schäfer-Korting, M, 1982
)
0.49
" Hydralazine bioavailability in the fast acetylator group (9."( Hydralazine kinetics after single and repeated oral doses.
Lin, MS; Ludden, TM; McNay, JL; Shepherd, AM, 1980
)
2.61
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" The African-American Heart Failure Trial is the first prospective trial designed to test a novel therapy that enhances endothelial function and nitric oxide bioavailability in African-American patients with advanced heart failure."( Endothelial dysfunction and nitric oxide enhancing therapy: a new approach to the treatment of heart failure.
Taylor, AL,
)
0.13
"We investigated the acute or chronic effects of angiotensin (Ang) II on the bioavailability of NO in Ang II-infused rabbits using the catheter-type NO sensor."( Effects of angiotensin II on NO bioavailability evaluated using a catheter-type NO sensor.
Akasaka, T; Goto, M; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Yoshida, K, 2006
)
0.33
" Given this, the authors hypothesized that low NO bioavailability could reduce SKMVD in normal rats, independent of any systemic pathologies associated with the metabolic syndrome, and that this would be correlated with increased angiostatin production."( Angiostatin does not contribute to skeletal muscle microvascular rarefaction with low nitric oxide bioavailability.
Basile, DP; Frisbee, JC; Samora, JB, 2007
)
0.34
" Vessel structure, reactivity, and NO bioavailability were assessed in isolated vessels using standard techniques."( Angiostatin does not contribute to skeletal muscle microvascular rarefaction with low nitric oxide bioavailability.
Basile, DP; Frisbee, JC; Samora, JB, 2007
)
0.34
" The apparently modest effect on survival observed in V-HeFT II could be explained in part by the poor hydralazine bioavailability of the tablet preparation used in this trial."( Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
Cohn, JN; Packer, M; Sabolinski, ML; Tam, SW; Worcel, M, 2007
)
0.78
" Experimental data suggests that hydralazine, given concomitantly, attenuates the development of hemodynamic tolerance to ISDN and may increase bioavailability of NO in the vasculature."( Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure.
Jacob, RG; Thadani, U, 2008
)
0.95
" Considering pharmacokinetic properties of nifedipine such as rapid onset and long duration of action, the good oral bioavailability and less frequent side effects, it looks more preferable in hypertension emergencies of pregnancy than hydralazine."( Comparison of the efficacy of nifedipine and hydralazine in hypertensive crisis in pregnancy.
Esmaeili, S; Khazaeipour, Z; Motevalian, M; Pourmojieb, M; Rezaei, Z; Sharbaf, FR; Youefzadeh-Fard, Y, 2011
)
0.81
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Other studies have suggested that endothelial NO synthase (eNOS) dysfunction and attenuated NO bioavailability contribute to HFpEF morbidity and mortality."( Combination Sodium Nitrite and Hydralazine Therapy Attenuates Heart Failure With Preserved Ejection Fraction Severity in a "2-Hit" Murine Model.
Doiron, JE; Goodchild, TT; Koul, K; LaPenna, KB; Lefer, DJ; Li, Z; Moles, K; Patel, RB; Polhemus, DJ; Shah, SJ; Sharp, TE; Wang, JS; Xia, H, 2023
)
1.2

Dosage Studied

This network meta-analysis aimed to compare the efficacy and safety of intravenous (IV) hydralazine, oral nifedipine, and IV labetalol with different dosage regimens in the treatment of severe hypertension during pregnancy. Dosage ranged from 10 mg to 30 mg endralazine per day and from 75 mg to 200 mg hydralazines per day according to patient response.

ExcerptRelevanceReference
" This fluorescence can be utilized for the quantitative analysis of the drug in dosage forms."( Fluorescence of hydralazine in concentrated sulfuric acid.
Davis, BR; Minnet, KM; Naik, DV; Schulman, SG, 1976
)
0.6
" Angina and vertebro-basilar insufficiency were each aggravated in one patient, but resolved with dosage adjustment."( Hydrallazine and beta-blockade in refractory hypertension with characterization of acetylator phenotype.
Hunyor, SN, 1975
)
0.25
" 4) In the management of essential moderate or severe hypertension is preferable to employ a mild dosage of betablockers and diuretics, rather than use higher doses of a single agent."( [The role of renin after betablocking diuretic and vasodilator treatment in essential hypertension (author's transl)].
Fusco, M; Lombardo, M; Valente, D, 1979
)
0.26
" At present, treatment should be based on the results of cardiac catheterisation and the dosage adjusted according to the rate of hepatic acetylation."( [Treatment of severe chronic cardiac insufficiency with dihydralazine. Short-and median-term results].
Alison, D; Latour, F; Lavigne, G; Masson, D; Morand, P, 1979
)
0.5
" In the dosage used, hydrallazine affected only the diastolic blood pressure, and when added to either bendrofluazide or bendrofluazide plus atenolol it produced a further mean reduction in pressure of 6 mm Hg."( Contribution of atenolol, bendrofluazide, and hydrallazine to management of severe hypertension.
Mitchell, JR; Wilcox, RG, 1977
)
0.26
"Pharmacokinetic methods that have been used to improve antihypertensive drug therapy, including antihypertensive dosage regimens, are reviewed."( Using pharmacokinetics in drug therapy. V: Contributions to developing dosage regimens for antihypertensive drugs.
Schumacher, GE, 1979
)
0.26
" The specific therapy can then be effectively and safely delivered by a careful analysis of the dose-response relation as identified by hemodynamic monitoring."( Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure.
Armstrong, PW, 1979
)
0.26
" Hydralazine can be determined in dosage forms that also contain varying quantities of reserpine and hydrochlorothiazide."( Colorimetric determination of hydralazine with 9-chloroacridine.
Chang, YC; Stewart, JT, 1979
)
1.46
" Dose-response relationships to K+ were determined in isolated strips of rabbit aorta."( Comparative evaluation of the in vitro effects of hydralazine and hydralazine acetonide on arterial smooth muscle.
Barron, K; Carrier, O; Du Souich, P; Haegele, KD; McLean, AJ; McNay, JL, 1977
)
0.51
"In 16 patients with hypertension, BP could not be controlled satisfactorily by treatment with propranolol alone (mean dosage 325 mg/day)."( Changes in plasma volume and extracellular fluid volume and after addition of hydralazine to propranolol treatment in patients with hypertension.
Ibsen, H; Jensen, HA; Leth, A; Rasmussen, K, 1978
)
0.49
" The average fall in mean arterial pressure for each dosage of hydralazine was no different with or without propranolol, even though propranolol inhibited rises in plasma renin activity and pulse due to hydralazine."( Synergistic effects of hydralazine and alpha- or beta-adrenergic blockers: the role of plasma renin activity.
Chin, BK; Das, B; Gutkin, M; Mezey, K; Modlinger, RS,
)
0.68
" The drugs could be given in a twice-daily dosage and had a much higher degree of patient acceptance."( Oxprenolol and hydrallazine in the treatment of hypertension.
Freeman, JW; Knight, LW, 1975
)
0.25
" The dosage schedules for magnesium sulfate and hydralazine, while empiric, have been extensively tested for both efficacy and toxicity."( Standardized treatment of 154 consecutive cases of eclampsia.
Pritchard, JA; Pritchard, SA, 1975
)
0.51
" Dose-response analysis indicated that L-NNA was 87 and 230 times more potent than L-NMA and L-NAA, respectively."( Comparison of the inhibitory potencies of N(G)-methyl-, N(G)-nitro- and N(G)-amino-L-arginine on EDRF function in the rat: evidence for continuous basal EDRF release.
Chaudhuri, G; Cuevas, JM; Ignarro, LJ; Vargas, HM, 1991
)
0.28
"Using an in vivo model of nitroglycerin tolerance in the CHF rat, we examined the effects of hydralazine bolus dosing during continuous nitroglycerin infusion."( Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure.
Bauer, JA; Fung, HL, 1991
)
0.89
"The dose-response effects of hexamethonium, prazosin and rauwolscine - a ganglionic blocker, alpha 1- and alpha 2-adrenoceptor antagonists, respectively - on mean arterial pressure (MAP) and mean circulatory filling pressure (MCFP), an index of body venous tone, were examined in conscious and unrestrained rats."( Effects of alpha 1- and alpha 2-adrenoceptor antagonists on venous tone in conscious rats.
D'Oyley, HM; Pang, CC, 1990
)
0.28
" Findings show that timing recommendations for dosing in relation to meals are not considered in these institutions when drug administration schedules are established."( Drug administration in relation to meals in the institutional setting.
Kinder, S; Lubischer, A; Strong, A; Wolff, H, 1991
)
0.28
" The dose was titrated; 24 received hydralazine and 26 captopril up to a maximum daily dosage of 225 mg and 75 mg respectively."( Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine.
Brooks, NH; Lawrence, GP; Schofield, PM; Testa, HJ; Ward, C, 1991
)
0.77
" Although designed as a titration study, important dose-response data were available for analysis with nonlinear mixed effect modeling (NONMEM)."( Hydralazine dose-response curve analysis.
Chang, I; Graves, DA; Muir, KT; Patel, B; Richards, W; Steiger, BW, 1990
)
1.72
" Both vasodilators depressed the pressor dose-response curves to BHT 920, while sparing those to methoxamine."( Calcium entry blockade and alpha-adrenergic responsiveness in vivo.
Pedrinelli, R; Tarazi, RC, 1985
)
0.27
"The dose-response effects of vasodilator drugs, nitroglycerin, sodium nitroprusside and hydralazine, on mean arterial pressure (MAP) and mean circulatory filling pressure (MCFP), an index of body venous tone, were investigated in conscious, unrestrained, intact rats as well as in rats treated with the ganglionic blocker, hexamethonium."( Effects of vasodilator drugs on venous tone in conscious rats.
D'Oyley, HM; Pang, CC; Tabrizchi, R, 1989
)
0.5
" Lisinopril reduced systolic blood pressure and inhibited serum ACE activity in both normal and diabetic rats in a dose-response fashion."( Effects of the angiotensin converting enzyme inhibitor, lisinopril, on normal and diabetic rats.
Hartmann, JF; Hayes, NS; Keegan, ME; Slater, EE; Szemplinski, M, 1988
)
0.27
" Dosage ranged from 10 mg to 30 mg endralazine per day and from 75 mg to 200 mg hydralazine per day according to patient response."( Comparative study of endralazine and hydralazine for the treatment of hypertension uncontrolled by a beta-blocker and diuretic.
Chazan, BI; Duff, DA; McCallum, A; Whaley, K, 1986
)
0.77
" Labetalol and prazosin also significantly shifted the dose-response curve to the right for phenylephrine but not for angiotensin II."( Analysis of the mechanism underlying the vasodilator action of carvedilol in pithed spontaneously hypertensive rats.
Akashi, A; Hashimoto, H; Kanda, A; Tanaka, M, 1988
)
0.27
" Dose-response studies (required to increase heart rate or systolic blood pressure by 25 beats/min and 20mm Hg, respectively) were performed with phenylephrine, angiotensin and isoprenaline after each drug, and placebo administration and the effects of physiological pressor stimuli were compared."( Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine.
Bompart, F; Graham, BR; Liu, JB; Prichard, BN; Tomlinson, B, 1988
)
0.48
"3 mg/kg) in presence of prazosin shifted the norepinephrine pressor dose-response curves to the right whereas it was ineffective in yohimbine-pretreated animals."( Calcium entry blockade by nitrendipine and alpha adrenergic responsiveness in vivo: comparison with noncalcium entry blocker vasodilators in absence and presence of phenoxybenzamine pretreatment.
Pedrinelli, R; Tarazi, RC, 1985
)
0.27
" Total collagen synthesis was substantially reduced in hydralazine-treated cells; the time course and the dose-response relationship were similar to those observed for the hydroxylases."( A paradoxical effect of hydralazine on prolyl and lysyl hydroxylase activities in cultured human skin fibroblasts.
Murad, S; Pinnell, SR; Tajima, S, 1985
)
0.82
" In isolated cat papillary muscles and rabbit right atria, cumulative hydralazine log dose-response curves (0."( Direct effects of hydralazine on cardiac contractile function, haemodynamics, and myocardial energetics in isolated myocardium.
Amsterdam, EA; Rendig, SV; Segel, LD, 1988
)
0.84
"The in vivo performance of hydralazine sustained-release dosage forms prepared using an ethylcellulose-coated drug:resin complex was studied in healthy males who were determined to be slow acetylators."( Relative bioavailability of immediate- and sustained-release hydralazine formulations.
Ludden, LK; Ludden, TM; Rotenberg, KS; Shepherd, AM; Woodworth, JR, 1988
)
0.81
" The duration of action also varied in the labetalol group, with the shortest duration occurring in those patients who required the highest dosage for BP control."( A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy.
Amon, E; Gonzalez, AR; Mabie, WC; Sibai, BM, 1987
)
0.55
" The dosage could be increased to 150 or 300 mg/day at weekly intervals if sitting diastolic blood pressure was not adequately controlled (greater than 90 mmHg)."( Comparative efficacy and safety of immediate-release and controlled-release hydralazine in black hypertensive patients.
Adir, J; Curry, CL; Janda, SM; Poku, CD; Rotenberg, KS; Taylor, RE, 1987
)
0.5
" In the first study, 101 patients on a fixed combination of atenolol 100mg and chlorthalidone 25mg who required additional or 'third line' therapy for proper control, were randomised to either felodipine or hydralazine and the dosage was increased if the supine diastolic blood pressure was greater than 90mm Hg."( The use of felodipine in the treatment of severe hypertension.
Muir, AL; Wathen, CG, 1987
)
0.46
"1-4%, w/w) in three separate experiments: (1) a 2-week dose-response study; (2) a 2-month long-term feeding study; and (3) a pregnancy study."( Effect of the antihypertensive drug hydralazine on mineral metabolism in the rat.
Keen, CL; Lönnerdal, B; Peters, JM, 1988
)
0.55
" Substantially, cadralazine does not exert any effect on cumulative dose-response curves of these agonists in both vessel preparations even with the highest concentration of 10(-4) mol/l."( Effects of cadralazine on contractions induced by norepinephrine, serotonin, angiotensin II and K+ in rabbit aortic and renal arterial strips.
Higashio, T; Kuroda, K, 1988
)
0.27
" Changes in hydrazinophthalazine-treated rats after dosing them with isoprenaline had a similar tendency but they were significantly lower than those found in healthy animals receiving isoprenaline only."( Effect of isoprenaline on tissue elastin content and serum elastolytic activity in normal and hydrazinophthalazine-treated rats.
Drózdz, M; Kucharz, E; Olczyk, K; Wieczorek, M, 1987
)
0.27
" With the dosage regimen used in this study there was a tendency towards more effective blood pressure control with dihydrallazine."( Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy.
Ashe, RG; Moodley, J; Philpott, RH; Richards, AM, 1987
)
0.56
" Daily oral dosing of hydralazine (2 mg/kg/day) for 14 weeks had little or no effect on SBP, but potentiated the antihypertensive effect of SA446."( [Antihypertensive effects of SA446, hydralazine and the combination on renal hypertensive rats and spontaneously hypertensive rats by long-term treatment].
Iso, T; Nakata, K; Nishimura, K; Takada, T; Yamauchi, H, 1986
)
0.86
" Intravenous dosing gave rapid and persistent labelling of blood vessels, particularly arteries, whilst radiolabel from orally administered drug was detectable in the vasculature in modest amounts only at 6 h, the longest interval studied."( Autoradiographic study of the distribution of [3H]- and [14C]-hydrallazine in the rat.
Baker, JR; Bullock, GR; Williamson, IH, 1985
)
0.27
" All the hydrazones studied had an effective hypotensive effect after a high dosing (10 mg/kg); however, their potency was much smaller than that of HP, when plasma-free concentration-response curves were compared."( Pharmacokinetics of formation and excretion of some metabolites of hydralazine and their hypotensive effect in rats.
Iwaki, M; Ogiso, T; Ohtsuki, N, 1985
)
0.51
" CaCl2 dose-response (in the presence of 10(-5) mol."( Mechanism of hydralazine-induced relaxation of arterial smooth muscle.
Aloamaka, CP; Ebeigbe, AB, 1985
)
0.64
"Short-term therapy with oral hydralazine can favorably affect abnormal hemodynamics in patients with congestive heart failure, but the range of dosage is large."( Determinants of systemic availability of oral hydralazine in heart failure.
Crawford, MH; Kennedy, GT; Ludden, TM, 1985
)
0.82
"The action, efficient dosage and tolerance of a pure vasodilator, dihydralazine, used for the treatment of severe heart failure were studied in 30 children aged 1 month to 14 years."( [Dihydralazine treatment of cardiac insufficiency in children].
Fontaine, JL; Girardet, JP; Liechtmaneger, H; Verlhac, S, 1985
)
1.13
" Blood pressure variation through one dosing interval increased 42% when hydralazine was given but was not altered by nitrendipine."( Efficacy and safety comparison of nitrendipine and hydralazine as antihypertensive monotherapy.
Deedwania, PC; Fagan, TC; Mehta, JL; Sternleib, C; Vlachakis, N, 1984
)
0.75
" 2 Isoprenaline heart rate dose-response curves showed parallel shifts to the right after oral prizidilol, indicating antagonism by this compound at beta-adrenoceptors in the heart."( An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride.
Curry, PV; Pitcher, DW; Trounce, JR, 1982
)
0.26
" It is concluded that the acetylator phenotype does not affect the therapeutic efficacy or dosage requirement of endralazine."( Endralazine, a new peripheral vasodilator: absence of effect of acetylator status on antihypertensive effect.
Bogers, WA; Holmes, DG; Huunan-Seppala, A; Wideroe, B; Wideroe, TE, 1983
)
0.27
" A dosage of 100mg twice daily will often be adequate to control mild hypertension and the use of even lower doses has been reported."( Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
Prichard, BN, 1984
)
0.27
" Blood pressure control remained good during this time, and the dosage was slightly reduced."( Endralazine, a new peripheral vasodilator--a randomized cross-over trial against dihydralazine.
Axthelm, T; Kirch, W,
)
0.36
" In the second protocol, young SHRs (4 weeks of age) were treated with the same dosage of hydralazine until 16 weeks of age."( Independence of blood pressure and locomotor hyperactivity in normotensive and genetically hypertensive rat.
Atwater, DG; Gellis, JE; Hendley, ED; Low, WC; Whitehorn, D, 1983
)
0.49
" Vasodilators are active within a fairly wide dosage range, making individualized dosages requisite."( [Antihypertensive vasodilators].
Plouin, PF, 1983
)
0.27
" Apart from the hydrochlorothiazide dosage which was fixed, the dosage of the other active drugs was titrated incrementally until the target blood pressure level was achieved."( An appraisal of antihypertensive efficacy and adverse reactions with two drug regimens: enalapril maleate as part of triple therapy compared to conventional triple therapy in moderate to severe hypertension.
Fernandez, PG; Galway, AB; Kim, BK, 1984
)
0.27
"One of the principal uses suggested for the microencapsulation of pharmaceuticals has been the preparation of the sustained release dosage form."( Formulation and release of dihydralazine sulphate from tabletted microcapsules.
Hincal, AA; Oner, L; Yalabik-Kaş, HS,
)
0.42
" The acute blood-pressure-lowering effect of nifedipine in the Dahl salt-sensitive rat was characterized by a rapid onset of action, the minimal effective oral dosage (0."( Factors involved in the antihypertensive action of calcium antagonists.
Garthoff, B; Kazda, S; Knorr, A; Thomas, G,
)
0.13
" However, basal blood pressure was significantly lowered after 4 days of treatment with urapidil at the high dosage and no further reduction was achieved on the fifth day."( Blood pressure response and renin release following 4 days of treatment with dihydralazine and urapidil in conscious dogs.
Bacher, S; Beck, A; Kraupp, O; Raberger, G; Seitelberger, R, 1984
)
0.5
" Hydralazine is an effective antihypertensive drug that has come to be used in restricted dosage (not more than 200 mg daily) because of its risk of inducing the lupus syndrome."( The lupus syndrome induced by hydralazine: a common complication with low dose treatment.
Cameron, HA; Ramsay, LE, 1984
)
1.47
" The amperometric method is highly specific and may be used to determine hydralazine hydrochloride in the presence of other drugs commonly found in its pharmaceutical dosage forms or administered concurrently in therapeutic situations."( Amperometric determination of hydralazine hydrochloride in a flowing stream at the glassy carbon electrode.
Shah, MH; Stewart, JT, 1984
)
0.79
" As revealed by the dose-response curves in SHR both drugs produce similar maximal drops in blood pressure by about 54%."( Differential influence of the calcium antagonist nitrendipine and the vasodilator hydralazine on normal and elevated blood pressure.
Garthoff, B; Knorr, A, 1984
)
0.49
" It is therefore concluded that continuous control of water intake and analysis of the stability of the drug is essential for the establishment of proper dose-response relationships."( Drinking water and drug dosage in rat studies.
Jakobsen, P; Jespersen, LT; Mikkelsen, EO; Pedersen, OL, 1983
)
0.27
" Current recommendations on hydralazine dosage are unsatisfactory for the 40% of hypertensive patients who are rapid acetylators."( Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
Freestone, S; Ollerenshaw, JD; Phillips, FC; Ramsay, LE; Silas, JH; Tucker, GT, 1984
)
0.8
" Responses were assessed by measuring blood pressure and heart rate for 8 hr after dosing and integrating the changes observed over time in order to obtain a mean value."( Baroreflex sensitivity as a determinant of responses to hydralazine in dogs.
Vidrio, H, 1983
)
0.51
" Fifty-one weanling Hartley guinea pigs were divided into five groups which received either procainamide, hydralazine, acetanilide, caffeine or saline sc for 55 weeks; drug dosage was 10 mg/kg initially and was increased incrementally to 40 mg/kg by 10 months except for hydralazine, which was increased to 20 mg/kg."( Drug-induced antinuclear antibodies in the guinea pig.
Balazs, T; Robinson, CJ, 1982
)
0.48
" Dose-response relationships for endralazine, hydralazine and diazoxide, administered intravenously, were compared, and the interactions of endralazine with the ganglionic blocking agent, pentolinium, or with adrenaline, noradrenaline and angiotensin II were examined."( Studies in the rat on endralazine, a new antihypertensive drug structurally related to hydralazine.
Oates, HF; Stoker, LM,
)
0.61
" Lesser problems include the construction of effective dosage schedules, deleterious effects after sudden withdrawal, development of tolerance, and side effects."( The longer term efficacy of vasodilators in heart failure.
Hernandez, J; Owens, CW, 1982
)
0.26
" Substantial and prolonged falls in blood pressure were observed following oral dosing with 3 mg/kg of nifedipine in renal hypertensive rats, with 10 mg/kg of nifedipine in normotensive and spontaneously hypertensive rats and with 10 mg/dg of hydralazine in all three groups of animals."( Antihypertensive effects of nifedipine on conscious normotensive and hypertensive rats.
Fujie, K; Kubo, T; Misu, Y; Yamashita, M, 1981
)
0.44
" Pyd action is modified only by the most active purine 2-Cl-adenosine, which displaces the dose-response curves to the right."( Interactions between hydralazine, propildazine and purines on arterial smooth muscle.
Chevillard, C; Saiag, B; Worcel, M, 1981
)
0.58
" Long-term vasodilator therapy may alter the maintenance dosage of digoxin required for optimal treatment of patients in congestive heart failure."( Acute vasodilator therapy increases renal clearance of digoxin in patients with congestive heart failure.
Benowitz, NL; Carlson, CJ; Cogan, JJ; Humphreys, MH; Rapaport, E, 1981
)
0.26
" The applicability of acetylator phenotyping for individualization of hydralazine dosage regimens merits further evaluation."( Plasma concentration and acetylator phenotype determine response to oral hydralazine.
Lin, MS; Ludden, TM; McNay, JL; Musgrave, GE; Shepherd, AM,
)
0.6
" Blood and saliva samples were taken at intervals after dosing and analysed for drug."( Effect of food on the absorption of hydralazine in man.
Graham, BR; Hernandez, R; Prichard, BN; Walden, RJ; Witts, D, 1981
)
0.54
" Thus, the dose and dosing interval of hydralazine needed to induce hemodynamic improvement in patients with severe heart failure are variable and require individualization."( Hemodynamic evaluation of hydralazine dosage in refractory heart failure.
Gorlin, R; Herman, MV; Medina, N; Meller, J; Packer, M, 1980
)
0.83
" After 3 weeks of treatment with hydralazine, cumulative dose-response relationships to NA were studied using aortic and portal vein strips from hydralazine-treated and control rats."( Hydralazine prevents changes in the contractile response of aortic but not portal vein strips in hypertensive rats.
Pang, CC; Sutter, MC, 1980
)
1.99
" Dose-response curves to norepinephrine in the presence of hydralazine were shifted to the right in parallel fashion at an only slight reduction of the maximum response."( Studies on the direct vasodilator effect of hydralazine in the isolated rabbit renal artery.
Gross, F; Khayyal, M; Kreye, VA, 1981
)
0.77
" Administration of 5 mg/kg of hydralazine following dosing with the PFOB emulsion reduced the 19F signal intensity from the murine tumors RIF-1 and KHT and from the human tumour HT29 with no or little reduction in the SCCVII/Ha murine and HX118 human tumours."( [Use of fluorine-19 nuclear resonance spectroscopy for the measurement of changes induced in blood perfusion volume in experimental tumors in vivo].
Adams, G; Counsell, C; Thomas, C; Wood, P, 1993
)
0.57
"Early development of nitrate tolerance with either continuous administration of intravenous or topical nitrate preparations or frequent dosing of oral nitrates leads to significant attenuation of nitrate-mediated hemodynamic and anti-ischemic effects."( Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure.
Ajit-Uppal, J; Elkayam, U; Gogia, H; Johnson, JV; Mehra, A; Parikh, S; Raman, M, 1995
)
0.52
"The combination of hydralazine and nitrates has been shown to provide long-term benefit in congestive heart failure, despite a nitrate dosage that should induce tolerance."( Interaction between hydralazine and nitrovasodilators in vascular smooth muscle.
Berkenboom, G; Fontaine, J; Unger, P, 1993
)
0.94
" Cerebral infarctions occurred whether or not SHRSP rats were treated with an antihypertensive agent when they were fed a high dosage of L-NNA."( Detailed examination of vascular lesions triggered by an inhibitor of endothelium-derived relaxing factor.
Fujino, H; Ikeda, K; Kubota, A; Nara, Y; Numano, F; Tagami, M; Yamori, Y, 1995
)
0.29
" In SHR cells, the maximal slope conductance of the levcromakalim-evoked current, normalized by cell capacitance, was decreased, and the dose-response curve was shifted to the right compared with WKY cells."( Impaired action of levcromakalim on ATP-sensitive K+ channels in mesenteric artery cells from spontaneously hypertensive rats.
Abe, I; Fujii, K; Fujishima, M; Nagao, T; Ohya, Y; Setoguchi, M, 1996
)
0.29
" Dose-response relationships were analyzed by probit dose-response methods and protective ratios for each compound were computed."( The effects of EDRF/NO releasers or calcium ionophore A23187 on cyanide toxicity in mice.
Baskin, SI; Lempka, JC; Nealley, EW, 1996
)
0.29
" The specimens were precontracted with norepinephrine (1 microM) and a dose-response curve was established by adding cumulatively either sodium nitroprusside (n = 7), cromokalin (n = 7), or hydralazine (n = 7) at increasing concentrations."( Drug-induced vasodilation: the effects of sodium nitroprusside, hydralazine, and cromakalin on the rabbit carotid artery: in vitro and in vivo study.
Cromeens, D; Evans, GR; Gherardini, G; Gürlek, A; Joly, GA; Wang, B, 1997
)
0.73
" In study 2, the dose-response relationship for ANG II infusion (200, 350, and 500 ng."( Mechanisms contributing to angiotensin II regulation of body weight.
Cassis, LA; Fettinger, MJ; Lodder, RA; Marshall, DE; Rosenbluth, B, 1998
)
0.3
" ISO displaced to the left the dose-response curves to all nitrovasodilators and increased the negative logarithm of their median effective concentration (EC50) values."( Potentiation by isoniazid of relaxation induced by nitrovasodilators in rat aorta.
Fernández, G; Vidrio, H, 1998
)
0.3
"The stability of five drugs commonly prescribed for use in oral liquid dosage forms but not commercially available as such was studied."( Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids.
Allen, LV; Erickson, MA, 1998
)
0.53
"Thirty THM aged 12 weeks were distributed equally to a lisinopril dosage group, a hydralazine dosage group, and an untreated group."( Tissue-localized angiotensin II enhances cardiac and renal disorders in Tsukuba hypertensive mice.
Fukamizu, A; Ishikawa, K; Kai, T; Kurooka, A; Murakami, K; Shimada, S; Sugimura, K; Takenaka, T, 1998
)
0.53
" A low dosage of fosinopril (5 mg/kg/d) that was still adequate to reduce their plasma ACE activity and LDL propensity to lipid peroxidation was insufficient to lower their blood pressure."( The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice.
Attias, J; Breslow, JL; Brodsky, S; Coleman, R; Hayek, T; Keidar, S; Smith, J, 1999
)
0.3
" The DIL-causing potential of each chemical group is a measurable intrinsic characteristic of that group, and the probability of DIL appearance is directly proportional to the total dosage of the drug in question."( A predictive equation for drug-induced lupus.
Adhami, E, 2003
)
0.32
" To select the most appropriate drug therapy for patients with heart failure, clinicians should consider results from clinical trials in specific patient populations, adverse-event profiles, tolerability, cost, and dosing regimens."( Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.
Norgard, NB; Stark, JE, 2008
)
0.35
" The hydralazine dose was given according with the acetylator phenotype, and valproate was dosed at 30 mg/kg/day."( Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
Arias-Bofill, D; Candelaria, M; Cervera, E; de la Cruz-Hernández, E; Dueñas-Gonzalez, A; González-Fierro, A; Herrera, A; Labardini, J; Pérez-Cárdenas, E; Taja-Chayeb, L; Trejo-Becerril, C; Vidal, S, 2011
)
2.33
" Among blacks with hypertensive chronic kidney disease, neither PM (bedtime) dosing of once-daily antihypertensive nor the addition of drugs taken at bedtime significantly reduced nocturnal BP compared with morning dosing of antihypertensive medications."( A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Agodoa, LY; Appel, LJ; Bakris, GL; Charleston, J; Contreras, G; Gabbai, F; Greene, T; Hiremath, L; Jamerson, K; Kendrick, C; Kusek, JW; Lash, JP; Lea, J; Miller, ER; Phillips, RA; Rahman, M; Rostand, S; Toto, R; Wang, X; Wright, JT, 2013
)
0.39
" The assay employs incubation of dosage formulation suspensions with hydralazine hydrochloride under mildly acidic conditions and elevated temperatures, where formaldehyde is derivatized to yield fluorescent s-triazolo-[3,4-a]-phthalazine."( A High-Temperature, High-Throughput Method for Monitoring Residual Formaldehyde in Vaccine Formulations.
Hentz, NG; Kitchener, RL; Stallings, KD, 2014
)
0.64
"Adequate initial dosing of antihypertensive treatment has the potential to reduce time to blood pressure control and possibly time to alteplase therapy."( Time to Blood Pressure Control Before Thrombolytic Therapy in Patients With Acute Ischemic Stroke: Comparison of Labetalol, Nicardipine, and Hydralazine.
Cortes, J; Hall, AB; McKay, C, 2015
)
0.62
" Hydralazine was dosed according to the acetylation genotype of patients (slow acetylators 83 mg daily; fast acetylators 182 mg daily), and valproate was dosed at 30 mg/kg/day."( Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).
Burgos, S; Candelaria, M; Dueñas-Gonzalez, A; Espinoza, R; Ponce, M, 2017
)
1.62
" Further research is required to delineate the multifactorial nature of RI-ED and to determine if TPOm with modified dosing regimens can mitigate against nerve injury either through direct or vascular protective effects."( Clarifying the Relative Impacts of Vascular and Nerve Injury That Culminate in Erectile Dysfunction in a Pilot Study Using a Rat Model of Prostate Irradiation and a Thrombopoietin Mimetic.
Ashcraft, KA; Dewhirst, MW; Eichenbaum, G; Faught, AM; Hannan, JL; Koontz, BF; Pak, ES; Patel, P; Zhang, X, 2019
)
0.51
" Serial blood samples were collected over 1 dosing interval, and steady-state noncompartmental PK parameters were estimated."( Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy.
Cusumano, M; Easterling, TR; Han, LW; Hebert, MF; Phillips, BR; Risler, LJ; Ryu, RJ; Shen, DD, 2019
)
0.75
"To allow for tailored dosing and overcome swallowing difficulties, compounded liquid medication is often required in pediatric patients."( Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4.
Anagnostou, K; Cunha, CN; da Silva, SL; Dijkers, E; Ferreira, AO; Polonini, H,
)
0.34
" With appropriate guidance on the usage of NAT2 genotype, clinicians can adopt a personalized approach to hydralazine dosing and prescription, enabling more efficient and safe treatment of resistant hypertension."( Genotype-Guided Hydralazine Therapy.
Collins, KS; Cooper-DeHoff, RM; Eadon, MT; Elchynski, AL; Raviele, ALJ; Woodcock, AM; Zhao, Y, 2020
)
1.12
"This network meta-analysis aimed to compare the efficacy and safety of intravenous (IV) hydralazine, oral nifedipine, and IV labetalol with different dosage regimens in the treatment of severe hypertension during pregnancy."( Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials.
Cheng, Y; Jiang, YF; Li, JB; Wu, HZ; Yu, D; Zhu, ZN, 2022
)
1.19
" Initial dosing with nicardipine lowered acute diastolic BP than labetalol (least square mean difference (labetalol-nicardipine)=5."( Initial antihypertensive agent effects on acute blood pressure after intracerebral haemorrhage.
Behymer, TP; Bettin, M; Christianson, T; Coleman, ER; Divani, A; Flaherty, ML; Gilkerson, LA; James, ML; King, NKK; Krishnamoorthy, V; Langefeld, CD; McCauley, JL; Ng, Y; Qi, W; Shah, S; Testai, FD; Walsh, KB; Woo, D, 2022
)
0.72
" The current article reviews the clinical pharmacokinetics (PK) of hydralazine, which can be useful for clinicians in optimizing its dose and dosing frequency to avoid adverse effects and unexpected interactions that could risk patients' lives."( A review on the clinical pharmacokinetics of hydralazine.
Alqahtani, F; Ashraf, W; Hussain, I; Imran, I; Khalid, S; Majeed, A; Rasool, MF; Rehman, AU; Saeed, H; Shahzad Qamar, A; Zamir, A, 2022
)
1.22
"Notably, on day 35, after drug treatment, we observed that mice that received vitamin E at a dosage of 50 mg/kg (3."( In vivo ameliorative effects of vitamin E against hydralazine-induced lupus.
Githaiga, FM; Ngugi, MP; Omwenga, GI, 2023
)
1.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
vasodilator agentA drug used to cause dilation of the blood vessels.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
phthalazines
azaarene
ortho-fused heteroareneAn ortho-fused compound in which at least one of the rings contains at least one heteroatom.
hydrazinesHydrazine (diazane) and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (51)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency12.55940.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency12.58930.177814.390939.8107AID2147
LuciferasePhotinus pyralis (common eastern firefly)Potency5.54930.007215.758889.3584AID411; AID624030
thioredoxin reductaseRattus norvegicus (Norway rat)Potency18.88760.100020.879379.4328AID488772; AID588456
phosphopantetheinyl transferaseBacillus subtilisPotency35.94100.141337.9142100.0000AID1490; AID2701; AID2707
ATAD5 protein, partialHomo sapiens (human)Potency0.59280.004110.890331.5287AID493106; AID493107
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624146
ThrombopoietinHomo sapiens (human)Potency0.03980.02517.304831.6228AID917; AID918
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency5.01190.011212.4002100.0000AID1030
ParkinHomo sapiens (human)Potency0.41090.819914.830644.6684AID720573
arylsulfatase AHomo sapiens (human)Potency26.85451.069113.955137.9330AID720538
pyruvate kinaseLeishmania mexicana mexicanaPotency1.99530.398113.744731.6228AID945; AID959
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency7.94330.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency12.58930.00207.533739.8107AID891
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency2.59290.01262.451825.0177AID485313
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency2.64750.316212.443531.6228AID902; AID924
ras-related protein Rab-9AHomo sapiens (human)Potency2.31090.00022.621531.4954AID485297
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency14.12540.00798.23321,122.0200AID2546
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.03460.005612.367736.1254AID624032
survival motor neuron protein isoform dHomo sapiens (human)Potency3.98110.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency8.28520.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.02820.00106.000935.4813AID943
lamin isoform A-delta10Homo sapiens (human)Potency3.16230.891312.067628.1838AID1487
pyruvate kinase PKM isoform bHomo sapiens (human)Potency7.94332.511912.262825.1189AID954; AID958
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Integrin beta-3Homo sapiens (human)Potency3.24650.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency3.24650.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Ataxin-2Homo sapiens (human)Potency0.44670.011912.222168.7989AID588378
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency8.28521.000012.224831.6228AID885
Single-stranded DNA cytosine deaminaseHomo sapiens (human)Potency38.728328.183860.145389.1251AID1347427; AID1347430
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
MyeloperoxidaseHomo sapiens (human)IC50 (µMol)1.26500.02001.88117.6800AID1337095; AID1337096; AID1446226; AID1446231
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)IC50 (µMol)3.64900.11003.26419.0330AID625146
Aspartate aminotransferase, cytoplasmicHomo sapiens (human)IC50 (µMol)26.62005.39005.39005.3900AID1850919
LactoperoxidaseBos taurus (cattle)IC50 (µMol)1.20000.40002.42506.1000AID1446235
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (159)

Processvia Protein(s)Taxonomy
nucleotide-excision repairN-glycosylase/DNA lyaseHomo sapiens (human)
DNA damage responseN-glycosylase/DNA lyaseHomo sapiens (human)
negative regulation of double-strand break repair via single-strand annealingN-glycosylase/DNA lyaseHomo sapiens (human)
base-excision repairN-glycosylase/DNA lyaseHomo sapiens (human)
regulation of DNA-templated transcriptionN-glycosylase/DNA lyaseHomo sapiens (human)
response to oxidative stressN-glycosylase/DNA lyaseHomo sapiens (human)
response to radiationN-glycosylase/DNA lyaseHomo sapiens (human)
response to xenobiotic stimulusN-glycosylase/DNA lyaseHomo sapiens (human)
response to light stimulusN-glycosylase/DNA lyaseHomo sapiens (human)
response to estradiolN-glycosylase/DNA lyaseHomo sapiens (human)
cellular response to reactive oxygen speciesN-glycosylase/DNA lyaseHomo sapiens (human)
negative regulation of apoptotic processN-glycosylase/DNA lyaseHomo sapiens (human)
positive regulation of gene expression via chromosomal CpG island demethylationN-glycosylase/DNA lyaseHomo sapiens (human)
depurinationN-glycosylase/DNA lyaseHomo sapiens (human)
depyrimidinationN-glycosylase/DNA lyaseHomo sapiens (human)
response to ethanolN-glycosylase/DNA lyaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIN-glycosylase/DNA lyaseHomo sapiens (human)
response to folic acidN-glycosylase/DNA lyaseHomo sapiens (human)
cellular response to cadmium ionN-glycosylase/DNA lyaseHomo sapiens (human)
base-excision repair, AP site formationN-glycosylase/DNA lyaseHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
hydrogen peroxide catabolic processMyeloperoxidaseHomo sapiens (human)
response to yeastMyeloperoxidaseHomo sapiens (human)
hypochlorous acid biosynthetic processMyeloperoxidaseHomo sapiens (human)
respiratory burst involved in defense responseMyeloperoxidaseHomo sapiens (human)
defense responseMyeloperoxidaseHomo sapiens (human)
response to oxidative stressMyeloperoxidaseHomo sapiens (human)
response to mechanical stimulusMyeloperoxidaseHomo sapiens (human)
removal of superoxide radicalsMyeloperoxidaseHomo sapiens (human)
response to foodMyeloperoxidaseHomo sapiens (human)
response to lipopolysaccharideMyeloperoxidaseHomo sapiens (human)
low-density lipoprotein particle remodelingMyeloperoxidaseHomo sapiens (human)
hydrogen peroxide catabolic processMyeloperoxidaseHomo sapiens (human)
negative regulation of apoptotic processMyeloperoxidaseHomo sapiens (human)
defense response to fungusMyeloperoxidaseHomo sapiens (human)
response to gold nanoparticleMyeloperoxidaseHomo sapiens (human)
defense response to bacteriumMyeloperoxidaseHomo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
gluconeogenesisAspartate aminotransferase, cytoplasmicHomo sapiens (human)
2-oxoglutarate metabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
oxaloacetate metabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
glycerol biosynthetic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
aspartate metabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
aspartate catabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
glutamate metabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
Notch signaling pathwayAspartate aminotransferase, cytoplasmicHomo sapiens (human)
glutamate catabolic process to aspartateAspartate aminotransferase, cytoplasmicHomo sapiens (human)
glutamate catabolic process to 2-oxoglutarateAspartate aminotransferase, cytoplasmicHomo sapiens (human)
cellular response to insulin stimulusAspartate aminotransferase, cytoplasmicHomo sapiens (human)
response to glucocorticoidAspartate aminotransferase, cytoplasmicHomo sapiens (human)
fatty acid homeostasisAspartate aminotransferase, cytoplasmicHomo sapiens (human)
aspartate biosynthetic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
response to oxidative stressLactoperoxidaseBos taurus (cattle)
thiocyanate metabolic processLactoperoxidaseBos taurus (cattle)
antibacterial humoral responseLactoperoxidaseBos taurus (cattle)
hydrogen peroxide catabolic processLactoperoxidaseBos taurus (cattle)
cellular oxidant detoxificationLactoperoxidaseBos taurus (cattle)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
mRNA processingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytidine deaminationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
somatic diversification of immunoglobulinsSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
somatic hypermutation of immunoglobulin genesSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
B cell differentiationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
regulation of nuclear cell cycle DNA replicationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
defense response to bacteriumSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
positive regulation of gene expression via chromosomal CpG island demethylationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
isotype switchingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cellular response to lipopolysaccharideSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
DNA cytosine deaminationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
DNA demethylationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytidine to uridine editingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
negative regulation of single stranded viral RNA replication via double stranded DNA intermediateSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
defense response to virusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (53)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingN-glycosylase/DNA lyaseHomo sapiens (human)
damaged DNA bindingN-glycosylase/DNA lyaseHomo sapiens (human)
endonuclease activityN-glycosylase/DNA lyaseHomo sapiens (human)
protein bindingN-glycosylase/DNA lyaseHomo sapiens (human)
microtubule bindingN-glycosylase/DNA lyaseHomo sapiens (human)
oxidized purine nucleobase lesion DNA N-glycosylase activityN-glycosylase/DNA lyaseHomo sapiens (human)
enzyme bindingN-glycosylase/DNA lyaseHomo sapiens (human)
oxidized purine DNA bindingN-glycosylase/DNA lyaseHomo sapiens (human)
8-oxo-7,8-dihydroguanine DNA N-glycosylase activityN-glycosylase/DNA lyaseHomo sapiens (human)
class I DNA-(apurinic or apyrimidinic site) endonuclease activityN-glycosylase/DNA lyaseHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
chromatin bindingMyeloperoxidaseHomo sapiens (human)
peroxidase activityMyeloperoxidaseHomo sapiens (human)
protein bindingMyeloperoxidaseHomo sapiens (human)
heparin bindingMyeloperoxidaseHomo sapiens (human)
heme bindingMyeloperoxidaseHomo sapiens (human)
metal ion bindingMyeloperoxidaseHomo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
L-aspartate:2-oxoglutarate aminotransferase activityAspartate aminotransferase, cytoplasmicHomo sapiens (human)
phosphatidylserine decarboxylase activityAspartate aminotransferase, cytoplasmicHomo sapiens (human)
pyridoxal phosphate bindingAspartate aminotransferase, cytoplasmicHomo sapiens (human)
L-cysteine transaminase activityAspartate aminotransferase, cytoplasmicHomo sapiens (human)
peroxidase activityLactoperoxidaseBos taurus (cattle)
calcium ion bindingLactoperoxidaseBos taurus (cattle)
heme bindingLactoperoxidaseBos taurus (cattle)
thiocyanate peroxidase activityLactoperoxidaseBos taurus (cattle)
lactoperoxidase activityLactoperoxidaseBos taurus (cattle)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
cytidine deaminase activitySingle-stranded DNA cytosine deaminaseHomo sapiens (human)
protein bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
zinc ion bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
ubiquitin protein ligase bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
identical protein bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
RNA bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (57)

Processvia Protein(s)Taxonomy
nucleusN-glycosylase/DNA lyaseHomo sapiens (human)
nucleoplasmN-glycosylase/DNA lyaseHomo sapiens (human)
mitochondrial matrixN-glycosylase/DNA lyaseHomo sapiens (human)
cytosolN-glycosylase/DNA lyaseHomo sapiens (human)
nuclear matrixN-glycosylase/DNA lyaseHomo sapiens (human)
nuclear speckN-glycosylase/DNA lyaseHomo sapiens (human)
protein-containing complexN-glycosylase/DNA lyaseHomo sapiens (human)
nucleusN-glycosylase/DNA lyaseHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
extracellular regionMyeloperoxidaseHomo sapiens (human)
extracellular spaceMyeloperoxidaseHomo sapiens (human)
nucleusMyeloperoxidaseHomo sapiens (human)
nucleoplasmMyeloperoxidaseHomo sapiens (human)
lysosomeMyeloperoxidaseHomo sapiens (human)
secretory granuleMyeloperoxidaseHomo sapiens (human)
azurophil granule lumenMyeloperoxidaseHomo sapiens (human)
azurophil granuleMyeloperoxidaseHomo sapiens (human)
intracellular membrane-bounded organelleMyeloperoxidaseHomo sapiens (human)
extracellular exosomeMyeloperoxidaseHomo sapiens (human)
phagocytic vesicle lumenMyeloperoxidaseHomo sapiens (human)
extracellular spaceMyeloperoxidaseHomo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
nucleusAspartate aminotransferase, cytoplasmicHomo sapiens (human)
cytoplasmAspartate aminotransferase, cytoplasmicHomo sapiens (human)
cytosolAspartate aminotransferase, cytoplasmicHomo sapiens (human)
extracellular exosomeAspartate aminotransferase, cytoplasmicHomo sapiens (human)
cytosolAspartate aminotransferase, cytoplasmicHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
extracellular spaceLactoperoxidaseBos taurus (cattle)
cytoplasmLactoperoxidaseBos taurus (cattle)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nucleusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytoplasmSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytosolSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
protein-containing complexSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
nucleusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytoplasmSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
P-bodySingle-stranded DNA cytosine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (340)

Assay IDTitleYearJournalArticle
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID16577Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr)1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID16565Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr)1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID187011Tested for maximum fall in mean arterial pressure in Spontaneously hypertensive rats after peroral administration by using 1% methyl cellulose as vehicle at 0.5 mg/kg1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Heterocyclic analogues of the antihypertensive beta-adrenergic blocking agent (S)-2-[3-(ter-butylamino)-2-hydroxypropoxy]-3-cyanopyridine.
AID172264Blood pressure rating in spontaneously hypertensive rats, 24 hr after peroral administration of 10 mg/kg of compound1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives.
AID57653Tested for increase in iliac blood flow was measured in anesthetized dogs before timolol administered intra arterially at dose 1600 mg/kg1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Heterocyclic analogues of the antihypertensive beta-adrenergic blocking agent (S)-2-[3-(ter-butylamino)-2-hydroxypropoxy]-3-cyanopyridine.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1446241Substrate activity at MPO (unknown origin) assessed as pthalazine product formation at 4 uM preincubated with enzyme followed by H2O2 addition measured after 60 mins in presence of NaCl by LC-HRMS analysis2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID170695Percent change of heart rate in conscious DOCA Hypertensive rat at 5 hour after administration of dose of 10 mL (mg/kg po)1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Synthesis of some potential antihypertensive phthalazinyl- and quinoxalinylguanidines.
AID1135157Hypotensive activity at guinea pig assessed as decrease in blood pressure at 5 mg/kg, po after 3 hrs (Rvb = 112 +/- 2.6 to 122 +/- 2.7 mmHg)1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Synthesis and adrenergic beta-blocking activity of some 1,3-benzodioxole derivatives.
AID181976Increase in diastolic blood pressure for 0.3 ug/kg intravenous dosing of noradrenaline in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 2. Vasodilator activity of some 2-aryl-5-guanidino-1,3,4-thiadiazoles.
AID1148591Vasodilatory activity in conscious normotensive dog assessed as change in blood pressure at 0.25 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1135569Peripheral vasodilating activity in anesthetized trachea-cannulated mongrel dog assessed as increase in iliac blood flow at 400 ug administered intraarterially in presence of isoproterenol1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
An approach to peripheral vasodilator-beta-adrenergic blocking agents.
AID1149605Antihypertensive activity in po dosed renal hypertensive rat assessed as dose required to produce lowering of blood pressure to <= 130 mm after 2 to 24 hrs by photoelectric tensometric analysis1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Synthesis and antihypertensive activity of 1-amino-3,4-dihydroisoquinolines.
AID172140Blood pressure rating in spontaneously hypertensive rats, 10 hr after peroral administration of 1 mg/kg of compound1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives.
AID1130362Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 30 mg/kg, po after 24 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID58977Effect of compound (given intravenously) on heart rate in conscious renal hypertensive dogs at 20 h1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines.
AID172269Blood pressure rating in spontaneously hypertensive rats, 2 hr after peroral administration of 3 mg/kg of compound1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives.
AID1148596Vasodilatory activity in conscious normotensive dog assessed as change in heart rate at 0.1 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1215667Inhibition of CYP2D6 in human liver microsomes assessed as residual activity using dextromethorphan as substrate at 50 uM relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID1135544Antihypertensive activity in spontaneously hypertensive rat assessed as maximum fall in mean arterial pressure at 1 mg/kg, po1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
An approach to peripheral vasodilator-beta-adrenergic blocking agents.
AID194404The compound was tested for vasodilator activity in ganglion blocked rats. values denote percent change in mean arterial blood pressure 30 minutes after dosing rats at 1 mg/kg intravenously1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Antihypertensive indole derivatives of phenoxypropanolamines with beta-adrenergic receptor antagonist and vasodilating activity.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID174422Change in systolic blood pressure after 10 mg/kg oral administration in spontaneous hypertensive rats after 24 hr1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Antihypertensive pyrrolo[1,2-c]quinazolines and pyrrolo[1,2-c]quinazolinones.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1337095Inhibition of human MPO2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
From Dynamic Combinatorial Chemistry to
AID1850919Inhibition of GOT1 (unknown origin) using aspartic acid and alpha-ketoglutaric acid as substrates assessed as reduction in absorbance of NADH incubated for 20 mins in presence of MDH1 and NADH by HTS assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.
AID185886Maximum fall in systolic blood pressure at interval from 1 to 6 hours at a dose of 1 mg/kg when administered perorally in rats1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and antihypertensive activity of substituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1215666Inhibition of CYP2D6 in human liver microsomes assessed as residual activity using dextromethorphan as substrate at 25 uM relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID1130366Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 10 mg/kg, po after 24 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID181974Increase in diastolic blood pressure for 0.3 ug/kg intravenous dosing of angiotensin in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 2. Vasodilator activity of some 2-aryl-5-guanidino-1,3,4-thiadiazoles.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1148561Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as time required for persistence of hypotensive effect at 2.5 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1137389Vasodilatory activity in anesthetized dog assessed as increase in iliac blood flow at 400 mg, ia1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents.
AID1215668Inhibition of CYP3A in human liver microsomes assessed as residual activity using midazolam as substrate at 25 uM relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID58976Effect of compound (given intravenously) on heart rate in conscious renal hypertensive dogs at 12 h1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines.
AID1148552Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximum change in mean blood pressure at 2.5 mg/kg, po relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148601Vasodilatory activity in conscious normotensive dog assessed as cardiac output at 0.5 mg/kg, po by thermodilution method1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1130349Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 10 mg/kg, po after 4 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID1136801Peripheral vasodilating activity in mongrel dog assessed as increase in iliac blood flow at 1600 ug, ia1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
beta-Adrenergic blocking agents with acute antihypertensive activity.
AID1135155Hypotensive activity at guinea pig assessed as decrease in blood pressure at 5 mg/kg, po after 1 hr (Rvb = 112 +/- 2.6 to 122 +/- 2.7 mmHg)1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Synthesis and adrenergic beta-blocking activity of some 1,3-benzodioxole derivatives.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1135564Peripheral vasodilating activity in anesthetized trachea-cannulated mongrel dog assessed as increase in iliac blood flow at 1600 ug administered intraarterially in presence of isoproterenol1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
An approach to peripheral vasodilator-beta-adrenergic blocking agents.
AID467618Vasodilatory activity in Wistar rat thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction at 10 uM treated after phenylephrine challenge2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis and vasodilatory activity of some amide derivatives of 6-(4-carboxymethyloxyphenyl)-4,5-dihydro-3(2H)-pyridazinone.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1337098Inhibition of human MPO assessed as residual activity in absence of H2O2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
From Dynamic Combinatorial Chemistry to
AID191906Antihypertensive activity in DOCA/saline rat dosed at 2 mg/kg, administered perorally expressed as percent rise in heart rate after 2 h1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
synthesis and antihypertensive activity of 2-sulfonamido- and 2-sulfamido-1,3,4,6,7,11b alpha-hexahydro-2H-benzo[a]quinolizines.
AID190214Antihypertensive activity rating in conscious SHR after 24 h post dose at 3 mg/kg (po); Range 10-20%1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives. 2. 7-Acyl amide analogues.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID13788Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr)1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID181967Increase in diastolic blood pressure for 0.03 ug/kg intravenous dosing of angiotensin in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID1130365Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 10 mg/kg, po after 4 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID1137381Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as duration of action at 1 mg/kg, po1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents.
AID181973Increase in diastolic blood pressure for 0.3 ug/kg intravenous dosing of angiotensin in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID181312Antihypertensive activity in DOCA/saline rat dosed at 2 mg/kg, administered perorally expressed as percent fall in blood pressure after 6 h; NS is not significant1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
synthesis and antihypertensive activity of 2-sulfonamido- and 2-sulfamido-1,3,4,6,7,11b alpha-hexahydro-2H-benzo[a]quinolizines.
AID13782Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr)1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID1337096Irreversible inhibition of MPO (unknown origin)2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
From Dynamic Combinatorial Chemistry to
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID181978Increase in diastolic blood pressure for 1 Htz electrical stimulation in the pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 2. Vasodilator activity of some 2-aryl-5-guanidino-1,3,4-thiadiazoles.
AID1136796Antihypertensive activity in spontaneously hypertensive rat assessed as maximum fall in mean arterial pressure at 1 mg/kg, po1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
beta-Adrenergic blocking agents with acute antihypertensive activity.
AID170693Percent change of heart rate in conscious DOCA Hypertensive rat at 22 hour after administration of dose of 10 mL (mg/kg po)1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Synthesis of some potential antihypertensive phthalazinyl- and quinoxalinylguanidines.
AID174565Change in systolic blood pressure after 5 mg/kg oral administration in spontaneous hypertensive rats after 24 hr1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Antihypertensive pyrrolo[1,2-c]quinazolines and pyrrolo[1,2-c]quinazolinones.
AID174282Compound was tested for antihypertensive activity in rat after 24 hr postdose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, saludiuretic, and antihypertensive activity of 6,7-disubstituted 1(2H)- and 3,4-dihydro-1(2H)-phthalazinones.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1148605Vasodilatory activity in conscious normotensive dog assessed as total peripheral resistance at 0.5 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1148585Hypotensive activity in conscious renal hypertensive dog assessed as time required for persistence of hypotensive effect at 0.5 mg/kg, po measured for 8 hrs1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148594Vasodilatory activity in conscious normotensive dog assessed as change in blood pressure at 5 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID172267Blood pressure rating in spontaneously hypertensive rats, 2 hr after peroral administration of 1 mg/kg of compound1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives.
AID172265Blood pressure rating in spontaneously hypertensive rats, 24 hr after peroral administration of 3 mg/kg of compound1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives.
AID13957Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr)1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID1446230Inhibition of recombinant MPO (unknown origin) assessed as reduction in TMB peroxidation by measuring residual activity at 5 uM in presence of H2O2 and NaCl incubated for 5 mins followed by 100 fold enzyme dilution relative to control2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID172111Antihypertensive activity rating in conscious SHR after 10 hr post dose at 10 mg/kg (po); Range 20-30%1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives. 2. 7-Acyl amide analogues.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1148593Vasodilatory activity in conscious normotensive dog assessed as change in blood pressure at 0.5 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1215661Inhibition of CYP2C8 in human liver microsomes assessed as residual activity using paclitaxel as substrate at 50 uM relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID1135554Antihypertensive activity in spontaneously hypertensive rat assessed as duration of effect at 2 mg/kg, po1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
An approach to peripheral vasodilator-beta-adrenergic blocking agents.
AID173507Maximum percent decrease in blood pressure in SHR ( hour post dose in parentheses)1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives. 2. 7-Acyl amide analogues.
AID568396Antihypertensive activity against methyl prednisolone acetate-induced hypertension in albino rat assessed as reduction in mean arterial pressure at 2.6 mg/kg, ip after 1 hr by tail-cuff method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Triazole incorporated pyridazinones as a new class of antihypertensive agents: design, synthesis and in vivo screening.
AID1130356Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 3 mg/kg, po followed by second dosing at 24 hrs measured after 48 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID170694Percent change of heart rate in conscious DOCA Hypertensive rat at 3 hour after administration of dose of 10 mL (mg/kg po)1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Synthesis of some potential antihypertensive phthalazinyl- and quinoxalinylguanidines.
AID1130354Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 3 mg/kg, po after 24 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1148606Vasodilatory activity in conscious normotensive dog assessed as total peripheral resistance at 5 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID16602Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr)1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID16562Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr)1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1148560Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximum change in mean blood pressure at 1 mg/kg, po relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1130373Drug excretion in human assessed as para-hydroxylated metabolite1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID461002Inhibition of human recombinant DNMT3B expressed in baculovirus-insect cell system at 100 uM by scintillation counting2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation.
AID13969Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr)1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID1135156Hypotensive activity at guinea pig assessed as decrease in blood pressure at 5 mg/kg, po after 2 hrs (Rvb = 112 +/- 2.6 to 122 +/- 2.7 mmHg)1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Synthesis and adrenergic beta-blocking activity of some 1,3-benzodioxole derivatives.
AID1148598Vasodilatory activity in conscious normotensive dog assessed as change in heart rate at 5 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID16583Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr)1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1337099Inhibition of human MPO assessed as rate constant for reduction of PorFe(4)=O to PorFe(4)-OH in presence of H2O2 by stopped-flow method2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
From Dynamic Combinatorial Chemistry to
AID181969Increase in diastolic blood pressure for 0.1 ug/kg intravenous dosing of angiotensin in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID170448The compound was tested for antihypertensive activity in spontaneously hypertensive rats after peroral administration, at a dose of 4 mg/kg1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Antihypertensive indole derivatives of phenoxypropanolamines with beta-adrenergic receptor antagonist and vasodilating activity.
AID181983Increase in diastolic blood pressure for 6 Htz electrical stimulation in the pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID172263Blood pressure rating in spontaneously hypertensive rats, 24 hr after peroral administration of 1 mg/kg of compound1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives.
AID1135146Antagonist activity at guinea pig atrial beta adrenergic receptor assessed as isometric contractions at 5 x 10'-5 M by force displacement transducer1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Synthesis and adrenergic beta-blocking activity of some 1,3-benzodioxole derivatives.
AID60597Effect of compound (given intravenously) on systolic blood pressure in conscious renal hypertensive dogs at 4 h1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines.
AID1137380Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as duration of action at 0.5 mg/kg, po1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents.
AID174953Time taken for the decrease in arterial pressure was measured1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID1130361Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 30 mg/kg, po after 4 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID174281Compound was tested for antihypertensive activity in rat after 1 hr postdose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, saludiuretic, and antihypertensive activity of 6,7-disubstituted 1(2H)- and 3,4-dihydro-1(2H)-phthalazinones.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID174424Change in systolic blood pressure after 10 mg/kg oral administration in spontaneous hypertensive rats after 4 hr1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Antihypertensive pyrrolo[1,2-c]quinazolines and pyrrolo[1,2-c]quinazolinones.
AID173515Maximum percent decrease in heart rate of spontaneously hypertensive rats, 1 hours after peroral administration of 3 mg/kg of compound1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives.
AID181982Increase in diastolic blood pressure for 3 Htz electrical stimulation in the pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 2. Vasodilator activity of some 2-aryl-5-guanidino-1,3,4-thiadiazoles.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID181968Increase in diastolic blood pressure for 0.03 ug/kg intravenous dosing of angiotensin in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 2. Vasodilator activity of some 2-aryl-5-guanidino-1,3,4-thiadiazoles.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1148597Vasodilatory activity in conscious normotensive dog assessed as change in heart rate at 0.5 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID172120Antihypertensive activity rating in conscious SHR after 2 h post dose at 10 mg/kg (po)1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives. 2. 7-Acyl amide analogues.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1137391Vasodilatory activity in anesthetized dog assessed as increase in iliac blood flow at 3200 mg, ia1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1130371Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 3 mg/kg, po followed by second dosing at 24 hrs measured after 28 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1148592Vasodilatory activity in conscious normotensive dog assessed as change in blood pressure at 0.1 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID58975Effect of compound (given intravenously) on heart rate in conscious renal hypertensive dogs at 10 h1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines.
AID170700Percent change of mean arterial blood pressure in conscious DOCA Hypertensive rat at 2 hour, after administration of dose 10 mL (mg/kg po)1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Synthesis of some potential antihypertensive phthalazinyl- and quinoxalinylguanidines.
AID1130352Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 10 mg/kg, po followed by second dosing at 24 hrs measured after 48 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID181979Increase in diastolic blood pressure for 1.0 ug/kg intravenous dosing of noradrenaline in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID60595Effect of compound (given intravenously) on systolic blood pressure in conscious renal hypertensive dogs at 12 h1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1130372Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 3 mg/kg, po followed by second dosing at 24 hrs measured after 48 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID1148603Vasodilatory activity in conscious normotensive dog assessed as total peripheral resistance at 0.25 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1446226Inhibition of recombinant MPO (unknown origin) assessed as reduction in taurine chloramine production preincubated with enzyme and taurine followed by H2O2 addition measured after 5 mins2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID1215662Inhibition of CYP2C9 in human liver microsomes assessed as residual activity using diclofenac as substrate at 25 uM relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID1446239Irreversible inhibition of recombinant MPO (unknown origin) assessed as reduction in TMB peroxidation by measuring recovery of enzyme activity at compound to protein ratio of 110 preincubated for 15 mins followed 100 fold dilution with buffer containing H2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID188867Maximum percentage reduction in mean blood pressure and heart rate in metacorticoid (DOCA) hypertensive rats at a standard oral dose of 5 mg/kg1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 2. Vasodilator activity of some 2-aryl-5-guanidino-1,3,4-thiadiazoles.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1130355Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 3 mg/kg, po followed by second dosing at 24 hrs measured after 28 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID172141Blood pressure rating in spontaneously hypertensive rats, 10 hr after peroral administration of 10 mg/kg of compound1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives.
AID191907Antihypertensive activity in DOCA/saline rat dosed at 2 mg/kg, administered perorally expressed as percent rise in heart rate after 6 h; NS is not significant1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
synthesis and antihypertensive activity of 2-sulfonamido- and 2-sulfamido-1,3,4,6,7,11b alpha-hexahydro-2H-benzo[a]quinolizines.
AID60596Effect of compound (given intravenously) on systolic blood pressure in conscious renal hypertensive dogs at 20 h1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines.
AID1130351Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 10 mg/kg, po followed by second dosing at 24 hrs measured after 28 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID170702Percent change of mean arterial blood pressure in conscious DOCA Hypertensive rat at 3 hour, after administration of dose 10 mL (mg/kg po)1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Synthesis of some potential antihypertensive phthalazinyl- and quinoxalinylguanidines.
AID467619Vasodilatory activity in Wistar rat thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction treated after phenylephrine challenge2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis and vasodilatory activity of some amide derivatives of 6-(4-carboxymethyloxyphenyl)-4,5-dihydro-3(2H)-pyridazinone.
AID58979Effect of compound (given intravenously) on heart rate in conscious renal hypertensive dogs at 6 h1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID170699Percent change of mean arterial blood pressure in conscious DOCA Hypertensive rat at 1 hour, after administration of dose 10 mL (mg/kg po)1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Synthesis of some potential antihypertensive phthalazinyl- and quinoxalinylguanidines.
AID1215663Inhibition of CYP2C9 in human liver microsomes assessed as residual activity using diclofenac as substrate at 50 uM relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID176932Dose required to produce a 50% increase in blood flow to the autoperfused hindquarters of the anesthetized rat1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Design and synthesis of a series of combined vasodilator/beta-adrenoceptor antagonists based on 6-arylpyridazinones.
AID1148599Vasodilatory activity in conscious normotensive dog assessed as cardiac output at 0.25 mg/kg, po by thermodilution method1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID173524Maximum percent decrease in heart rate of spontaneously hypertensive rats, 4 hr after peroral administration of 10 mg/kg of compound1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives.
AID1135545Antihypertensive activity in spontaneously hypertensive rat assessed as maximum fall in mean arterial pressure at 2 mg/kg, po1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
An approach to peripheral vasodilator-beta-adrenergic blocking agents.
AID1446228Inhibition of recombinant MPO (unknown origin) assessed as reduction in TMB peroxidation by measuring residual activity at 5 uM in absence of H2O2 incubated for 5 mins followed by 100 fold enzyme dilution relative to control2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID58978Effect of compound (given intravenously) on heart rate in conscious renal hypertensive dogs at 4 h1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines.
AID58981Effect of compound (given intravenously) on heart rate in conscious renal hypertensive dogs at t8 h1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines.
AID1148578Hypotensive activity in conscious renal hypertensive dog assessed as maximum change in mean blood pressure at 1 mg/kg, po measured for 8 hrs relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1136803Peripheral vasodilating activity in mongrel dog assessed as increase in iliac blood flow at 400 ug, ia1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
beta-Adrenergic blocking agents with acute antihypertensive activity.
AID188866Maximum percentage reduction in mean blood pressure and heart rate in metacorticoid (DOCA) hypertensive rats at a standard oral dose of 5 mg/kg1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID60599Effect of compound (given intravenously) on systolic blood pressure in conscious renal hypertensive dogs at 8 h1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID181981Increase in diastolic blood pressure for 3 Htz electrical stimulation in the pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID1148602Vasodilatory activity in conscious normotensive dog assessed as cardiac output at 5 mg/kg, po by thermodilution method1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1135570Peripheral vasodilating activity in anesthetized trachea-cannulated mongrel dog assessed as increase in iliac blood flow at 3200 ug administered intraarterially in presence of isoproterenol1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
An approach to peripheral vasodilator-beta-adrenergic blocking agents.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID177366Dose required to produce a fall in blood pressure of 40 mmHg in the anesthetized rat1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Design and synthesis of a series of combined vasodilator/beta-adrenoceptor antagonists based on 6-arylpyridazinones.
AID1148595Vasodilatory activity in conscious normotensive dog assessed as change in heart rate at 0.25 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID186856Maximum fall in mean arterial blood pressure was measured in SH rats when compound was administered at 1 mg/kg perorally (0-6 hr)1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID1135578Blockade of isoprolerenol-induced tachycardia in iv dosed anesthetized trachea-cannulated mongrel dog assessed as heart rate1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
An approach to peripheral vasodilator-beta-adrenergic blocking agents.
AID13806Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr)1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID678719Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1135552Antihypertensive activity in spontaneously hypertensive rat assessed as maximum fall in mean arterial pressure at 0.5 mg/kg, po1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
An approach to peripheral vasodilator-beta-adrenergic blocking agents.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID408066Inhibition of 4-hydroxynonenal-induced carbonyl stress in HMEC1 cells assessed as prevention of increase in carbonylated protein level at 100 uM relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Development of novel antiatherogenic biaryls: design, synthesis, and reactivity.
AID58974Effect of compound (given intravenously) on heart rate in conscious renal hypertensive dogs at 0 h1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines.
AID170701Percent change of mean arterial blood pressure in conscious DOCA Hypertensive rat at 22 hour, after administration of dose 10 mL (mg/kg po)1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Synthesis of some potential antihypertensive phthalazinyl- and quinoxalinylguanidines.
AID1136804Peripheral vasodilating activity in mongrel dog assessed as increase in iliac blood flow at 3200 ug, ia1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
beta-Adrenergic blocking agents with acute antihypertensive activity.
AID13770Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr)1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1155747Vasorelaxant activity in Wistar rat endothelium-denuded thoracic aortic rings assessed as inhibition of phenylephrine-induced contraction2014European journal of medicinal chemistry, Jul-23, Volume: 82Synthesis, biological evaluation and structure-activity relationships of new phthalazinedione derivatives with vasorelaxant activity.
AID1446231Inhibition of recombinant MPO (unknown origin) assessed as reduction in LDL oxidation in presence of H2O2 and HCl after 5 mins by ELISA2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID172124Antihypertensive activity rating in conscious SHR after 2 hr post dose at 3 mg/kg (po); Range 20-30%1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives. 2. 7-Acyl amide analogues.
AID1130370Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 3 mg/kg, po after 24 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID170691Percent change of heart rate in conscious DOCA Hypertensive rat at 1 hour after administration of dose of 10 mL (mg/kg po)1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Synthesis of some potential antihypertensive phthalazinyl- and quinoxalinylguanidines.
AID1215669Inhibition of CYP3A in human liver microsomes assessed as residual activity using midazolam as substrate at 50 uM relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID182174Compound was tested at 1.5e-3M for inhibition of spontaneous activity in rat isolated portal vein1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and antihypertensive activity of substituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols.
AID185889Maximum fall in systolic blood pressure at interval from 1 to 6 hours at a dose of 3 mg/kg when administered perorally in rats1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and antihypertensive activity of substituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols.
AID1135561Antihypertensive activity in spontaneously hypertensive rat assessed as duration of effect at 0.5 mg/kg, po1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
An approach to peripheral vasodilator-beta-adrenergic blocking agents.
AID1137371Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximal fall in mean arterial pressure at 2 mg/kg, po1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID159523Inhibition of canine heart Phosphodiesterase 4 at 100 uM1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
New 5H-pyridazino[4,5-b]indole derivatives. Synthesis and studies as inhibitors of blood platelet aggregation and inotropics.
AID170692Percent change of heart rate in conscious DOCA Hypertensive rat at 2 hour after administration of dose of 10 mL (mg/kg po)1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Synthesis of some potential antihypertensive phthalazinyl- and quinoxalinylguanidines.
AID187012Tested for maximum fall in mean arterial pressure in Spontaneously hypertensive rats after peroral administration by using 1% methyl cellulose as vehicle at 1 mg/kg1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Heterocyclic analogues of the antihypertensive beta-adrenergic blocking agent (S)-2-[3-(ter-butylamino)-2-hydroxypropoxy]-3-cyanopyridine.
AID172142Blood pressure rating in spontaneously hypertensive rats, 10 hr after peroral administration of 3 mg/kg of compound1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives.
AID1130347Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 30 mg/kg, po followed by second dosing at 24 hrs measured after 28 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID170703Percent change of mean arterial blood pressure in conscious DOCA Hypertensive rat at 5 hour, after administration of dose 10 mL (mg/kg po)1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Synthesis of some potential antihypertensive phthalazinyl- and quinoxalinylguanidines.
AID80775Inhibition of ADP-induced platelet aggregation in guinea pig whole blood at 5*10e-4 M1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
New 5H-pyridazino[4,5-b]indole derivatives. Synthesis and studies as inhibitors of blood platelet aggregation and inotropics.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1148569Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as time required for persistence of hypotensive effect at 1 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1130367Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 10 mg/kg, po followed by second dosing at 24 hrs measured after 28 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID1137370Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximal fall in mean arterial pressure at 1 mg/kg, po1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents.
AID1148576Hypotensive activity in conscious renal hypertensive dog assessed as maximum change in mean blood pressure at 0.5 mg/kg, po measured for 8 hrs relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID174283Compound was tested for antihypertensive activity in rat after 4 hr postdose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, saludiuretic, and antihypertensive activity of 6,7-disubstituted 1(2H)- and 3,4-dihydro-1(2H)-phthalazinones.
AID1446256Selectivity ratio of IC50 for bovine milk LPO to IC50 for recombinant MPO (unknown origin)2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID1135577Blockade of isoprolerenol-induced hypotension in iv dosed anesthetized trachea-cannulated mongrel dog assessed as mean arterial pressure1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
An approach to peripheral vasodilator-beta-adrenergic blocking agents.
AID1215659Inhibition of CYP1A2 in human liver microsomes assessed as residual activity using phenacetin as substrate at 50 uM relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID1148604Vasodilatory activity in conscious normotensive dog assessed as total peripheral resistance at 0.1 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1130364Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 30 mg/kg, po followed by second dosing at 24 hrs measured after 48 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID1130346Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 30 mg/kg, po after 24 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1446252Cytotoxicity against NHDF assessed as reduction in cell viability after 72 hrs by MTT assay2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID1148551Toxicity in po dosed Sprague-Dawley rat assessed as mortality after 7 days1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID187014Tested for maximum fall in mean arterial pressure in Spontaneously hypertensive rats after peroral administration by using 1% methyl cellulose as vehicle at 2 mg/kg1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Heterocyclic analogues of the antihypertensive beta-adrenergic blocking agent (S)-2-[3-(ter-butylamino)-2-hydroxypropoxy]-3-cyanopyridine.
AID1137382Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as duration of action at 2 mg/kg, po1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents.
AID57656Tested for increase in iliac blood flow was measured in anesthetized dogs before timolol administered intra arterially at dose 400 mg/kg1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Heterocyclic analogues of the antihypertensive beta-adrenergic blocking agent (S)-2-[3-(ter-butylamino)-2-hydroxypropoxy]-3-cyanopyridine.
AID172131Antihypertensive activity rating in conscious SHR after 24 h post dose at 10 mg/kg (po); Range 10-20%1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives. 2. 7-Acyl amide analogues.
AID190213Antihypertensive activity rating in conscious SHR after 10 hr post dose at 3 mg/kg (po); Range 20-30%1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives. 2. 7-Acyl amide analogues.
AID1215665Inhibition of CYP2C19 in human liver microsomes assessed as residual activity using S-mephenytoin as substrate at 50 uM relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID1210795Inhibition of human liver cytosolic aldehyde oxidase using DACA as substrate by LC-MS/MS analysis relative to control2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.
AID181977Increase in diastolic blood pressure for 1 Htz electrical stimulation in the pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID60594Effect of compound (given intravenously) on systolic blood pressure in conscious renal hypertensive dogs at 10 h1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines.
AID1130353Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 3 mg/kg, po after 4 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID60598Effect of compound (given intravenously) on systolic blood pressure in conscious renal hypertensive dogs at 6 h1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID13992Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr)1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID1446235Inhibition of bovine milk LPO assessed as reduction in NaOSCN production in presence of H2O2/NaSCN after 5 mins2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID1215664Inhibition of CYP2C19 in human liver microsomes assessed as residual activity using S-mephenytoin as substrate at 25 uM relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID1148600Vasodilatory activity in conscious normotensive dog assessed as cardiac output at 0.1 mg/kg, po by thermodilution method1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1136795Antihypertensive activity in spontaneously hypertensive rat assessed as maximum fall in mean arterial pressure at 0.5 mg/kg, po1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
beta-Adrenergic blocking agents with acute antihypertensive activity.
AID181970Increase in diastolic blood pressure for 0.1 ug/kg intravenous dosing of angiotensin in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 2. Vasodilator activity of some 2-aryl-5-guanidino-1,3,4-thiadiazoles.
AID1215658Inhibition of CYP1A2 in human liver microsomes assessed as residual activity using phenacetin as substrate at 25 uM relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID486735Antihypertensive activity against methyl prednisolone acetate-indcuced hypertension in normotensive albino rat assessed as reduction in mean arterial pressure at 20 mg/kg, ip after 1 hr2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis, characterization and antihypertensive activity of pyridazinone derivatives.
AID174567Change in systolic blood pressure after 5 mg/kg oral administration in spontaneous hypertensive rats after 4 hr1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Antihypertensive pyrrolo[1,2-c]quinazolines and pyrrolo[1,2-c]quinazolinones.
AID1446261Acute toxicity in rat2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID1137369Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximal fall in mean arterial pressure at 0.5 mg/kg, po1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents.
AID1130344Toxicity in ip dosed CF-1 mouse after 48 hrs1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID1446229Inhibition of recombinant MPO (unknown origin) assessed as reduction in TMB peroxidation by measuring residual activity at 5 uM in presence of H2O2 incubated for 5 mins followed by 100 fold enzyme dilution relative to control2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID1136815Peripheral vasodilating activity in mongrel dog at 100 ug/kg, iv assessed as increase in iliac blood flow after 30 mins relative to control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
beta-Adrenergic blocking agents with acute antihypertensive activity.
AID1130348Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 30 mg/kg, po followed by second dosing at 24 hrs measured after 48 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID1135553Antihypertensive activity in spontaneously hypertensive rat assessed as duration of effect at 1 mg/kg, po1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
An approach to peripheral vasodilator-beta-adrenergic blocking agents.
AID181972Increase in diastolic blood pressure for 0.1 ug/kg intravenous dosing of noradrenaline in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 2. Vasodilator activity of some 2-aryl-5-guanidino-1,3,4-thiadiazoles.
AID1446236Inhibition of MPO (unknown origin) assessed as apparent bi-molecular rate constant for PorFe(4)=O radical reduction by stopped-flow spectroscopic analysis2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID1130345Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 30 mg/kg, po after 4 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID174423Change in systolic blood pressure after 10 mg/kg oral administration in spontaneous hypertensive rats after 2 hr1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Antihypertensive pyrrolo[1,2-c]quinazolines and pyrrolo[1,2-c]quinazolinones.
AID186853Maximum fall in mean arterial blood pressure was measured in SH rats when compound was administered at 0.5 mg/kg perorally (0-6 hr)1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID461001Inhibition of human recombinant DNMT1 expressed in baculovirus-insect cell system at 100 uM by scintillation counting2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation.
AID1148587Hypotensive activity in conscious renal hypertensive dog assessed as time required for persistence of hypotensive effect at 1 mg/kg, po measured for 8 hrs1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1130350Antihypertensive activity in spontaneously hypertensive rat assessed as drop in mean systolic blood pressure at 10 mg/kg, po after 24 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID57655Tested for increase in iliac blood flow was measured in anesthetized dogs before timolol administered intra arterially at dose 3200 mg/kg1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Heterocyclic analogues of the antihypertensive beta-adrenergic blocking agent (S)-2-[3-(ter-butylamino)-2-hydroxypropoxy]-3-cyanopyridine.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1130369Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 3 mg/kg, po after 4 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID181971Increase in diastolic blood pressure for 0.1 ug/kg intravenous dosing of noradrenaline in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID1136814Peripheral vasodilating activity in mongrel dog at 100 ug/kg, iv assessed as increase in iliac blood flow after 30 mins in presence of propranolol relative to control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
beta-Adrenergic blocking agents with acute antihypertensive activity.
AID181975Increase in diastolic blood pressure for 0.3 ug/kg intravenous dosing of noradrenaline in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 1. Synthesis of some 2-aryl-5-hydrazino-1,3,4-thiadiazoles with vasodilator activity.
AID1337097Inhibition of human MPO assessed as residual activity in presence of H2O22017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
From Dynamic Combinatorial Chemistry to
AID1130363Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 30 mg/kg, po followed by second dosing at 24 hrs measured after 28 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1136797Antihypertensive activity in spontaneously hypertensive rat assessed as maximum fall in mean arterial pressure at 2 mg/kg, po1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
beta-Adrenergic blocking agents with acute antihypertensive activity.
AID181980Increase in diastolic blood pressure for 1.0 ug/kg intravenous dosing of noradrenaline in pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 2. Vasodilator activity of some 2-aryl-5-guanidino-1,3,4-thiadiazoles.
AID181984Increase in diastolic blood pressure for 6 Htz electrical stimulation in the pithed rats1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Antihypertensive thiadiazoles. 2. Vasodilator activity of some 2-aryl-5-guanidino-1,3,4-thiadiazoles.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID185887Maximum fall in systolic blood pressure, intervals from 1 to 6 hours at a dose of 10 mg/kg administered per orally1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and antihypertensive activity of substituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols.
AID172268Blood pressure rating in spontaneously hypertensive rats, 2 hr after peroral administration of 10 mg/kg of compound1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives.
AID80784Inhibition of arachidonic acid induced platelet aggregation in guinea pig whole blood at 5*10e-4 M1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
New 5H-pyridazino[4,5-b]indole derivatives. Synthesis and studies as inhibitors of blood platelet aggregation and inotropics.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1137390Vasodilatory activity in anesthetized dog assessed as increase in iliac blood flow at 1600 mg, ia1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents.
AID1130368Antihypertensive activity in spontaneously hypertensive rat assessed as mean heart rate at 10 mg/kg, po followed by second dosing at 24 hrs measured after 48 hrs by tail cuff method relative to vehicle-treated control1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and antihypertensive activity of novel 3-hydrazino-5-phenyl-1,2,4-triazines.
AID60593Effect of compound (given intravenously) on systolic blood pressure in conscious renal hypertensive dogs at 0 h1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1446246Substrate activity at MPO (unknown origin) assessed as 2-amino-7-methoxy-4-methylquinazoline oxidation product formation at 4 uM measured after 60 mins in absence of H2O2 by LC-HRMS analysis2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID181306Antihypertensive activity in DOCA/saline rat dosed at 2 mg/kg, administered perorally expressed as percent fall in blood pressure after 2 h1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
synthesis and antihypertensive activity of 2-sulfonamido- and 2-sulfamido-1,3,4,6,7,11b alpha-hexahydro-2H-benzo[a]quinolizines.
AID174566Change in systolic blood pressure after 5 mg/kg oral administration in spontaneous hypertensive rats after 2 hr1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Antihypertensive pyrrolo[1,2-c]quinazolines and pyrrolo[1,2-c]quinazolinones.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1155746Vasorelaxant activity in Wistar rat endothelium-intact thoracic aortic rings assessed as inhibition of phenylephrine-induced contraction2014European journal of medicinal chemistry, Jul-23, Volume: 82Synthesis, biological evaluation and structure-activity relationships of new phthalazinedione derivatives with vasorelaxant activity.
AID186858Maximum fall in mean arterial blood pressure was measured in SH rats when compound was administered at 2 mg/kg perorally1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID1215660Inhibition of CYP2C8 in human liver microsomes assessed as residual activity using paclitaxel as substrate at 25 uM relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID1801344Fluorescence-based Assay from Article 10.1021/acschembio.5b00452: \\Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).\\2015ACS chemical biology, Oct-16, Volume: 10, Issue:10
Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,260)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902722 (63.90)18.7374
1990's640 (15.02)18.2507
2000's476 (11.17)29.6817
2010's332 (7.79)24.3611
2020's90 (2.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 114.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index114.79 (24.57)
Research Supply Index8.51 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index216.97 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (114.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials364 (7.95%)5.53%
Reviews369 (8.06%)6.00%
Case Studies276 (6.03%)4.05%
Observational8 (0.17%)0.25%
Other3,563 (77.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (42)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1 Protocol of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies [NCT00996060]Phase 129 participants (Actual)Interventional2008-07-31Completed
The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II [NCT02281838]Phase 2270 participants (Anticipated)Interventional2011-08-01Recruiting
The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation [NCT04217135]Phase 4400 participants (Anticipated)Interventional2017-01-01Recruiting
Assessment of Immediate Postoperative Delirium (IPD) in Adult Patients: Incidence, Implication of Type of Anesthesia and Identification of Other Etiological Factors [NCT03967496]402 participants (Actual)Observational [Patient Registry]2019-01-01Completed
"Phase III Clinical Trial: Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer" [NCT02446652]Phase 3230 participants (Anticipated)Interventional2015-07-31Not yet recruiting
Efficacy of Nifedipine Versus Hydralazine in Management of Severe Hypertension in Pregnancy - A Randomised Controlled Trial [NCT04435210]69 participants (Actual)Interventional2018-08-13Completed
A Four-arm, Single Dose, Two-Period, Pharmacokinetic Study of BiDil SR and IR Capsules and Commercial BiDil Tablets [NCT01587313]Phase 136 participants (Actual)Interventional2012-04-30Completed
Effect of Blood Pressure Reduction in Patients With Chronic Heart Failure - Randomized, Double-blind, Placebo-controlled Trial [NCT01255475]Phase 2/Phase 321 participants (Actual)Interventional2011-01-31Completed
Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients at a Tertiary Care Hospital of Karachi. [NCT02050529]Phase 2190 participants (Actual)Interventional2012-10-31Completed
Vascular Improvement With Olmesartan Medoxomil Study [NCT00772499]Phase 4100 participants (Actual)Interventional2002-11-30Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - M [NCT03514108]Phase 41,500 participants (Anticipated)Interventional2018-03-01Recruiting
Effect of Organic Nitrates and Hydralazine on Wave Reflections and Left Ventricular Structure and Function in Heart Failure With Preserved Ejection Fraction [NCT01516346]Phase 244 participants (Actual)Interventional2012-01-31Completed
Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial [NCT00963976]Phase 274 participants (Actual)Interventional2007-01-31Completed
Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Recurrent and Metastatic Cervical Cancer. [NCT00532818]Phase 3143 participants (Anticipated)Interventional2007-07-31Recruiting
Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Cisplatin-Resistant Recurrent Ovarian Cancer. [NCT00533299]Phase 3211 participants (Anticipated)Interventional2007-08-31Recruiting
[NCT00000499]Phase 20 participants Interventional1980-09-30Completed
Hydralazine as a Demethylating Agent in Rectal Cancer [NCT00575640]Phase 1/Phase 20 participants (Actual)Interventional2004-11-30Withdrawn(stopped due to No enrollment)
Hydralazine as Demethylating Agent in Breast Cancer [NCT00575978]Phase 1/Phase 20 participants (Actual)Interventional2004-06-30Withdrawn(stopped due to IRB request)
Blood Pressure After Endovascular Stroke Therapy-II: A Randomized Trial [NCT04116112]Phase 2120 participants (Actual)Interventional2020-01-17Completed
Effects of the Selective Phosphodiesterase Type 5 Inhibitor Sildenafil Citrate on Exercise Capacity and Vascular Function in Hypertensive Subjects [NCT00599235]30 participants (Actual)Interventional2007-03-31Completed
An International Randomised Controlled Trial to Establish the Effects of Low-dose rtPA and the Effects of Early Intensive Blood Pressure Lowering in Patients With Acute Ischaemic Stroke [NCT01422616]Phase 34,587 participants (Actual)Interventional2012-03-31Completed
The Effect of Hydralazine on the Early Stage of Alzheimer's Disease: A Randomized Clinical Trial [NCT04842552]Phase 3424 participants (Anticipated)Interventional2021-08-02Recruiting
A Prospective, Placebo-controlled, Double-blind, Randomized Study to Compare Hydralazine-isosorbide-dinitrate(HYIS) Versus Placebo on Top of Std Care in African Patients With Acute Heart Failure (AHF) and Left Ventricular Dysfunction [NCT01822808]Phase 3500 participants (Anticipated)Interventional2013-01-31Active, not recruiting
Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus [NCT02046395]Phase 428 participants (Actual)Interventional2012-01-31Completed
A Phase II Study of Epigenetic Therapy With Hydralazine and Magnesium Valproate to Overcome Chemotherapy Resistance in Refractory Solid Tumors [NCT00404508]Phase 215 participants Interventional2005-09-30Completed
Changes in Central Arterial Pressure When Comparing ACOG Hypertensive Urgency Protocols [NCT02933593]0 participants (Actual)Interventional2016-08-31Withdrawn(stopped due to PI withdrew the protocol)
The Effect of Aortic Impedance on Myocardial Relaxation [NCT00204984]17 participants (Actual)Interventional2005-05-31Completed
Hydralazine vs. Labetalol for the Management of Hypertensive Crisis in Patients With Hypertensive Disorders of Pregnancy. A Randomized Controlled Trial. [NCT01538875]Phase 3261 participants (Actual)Interventional2012-07-31Completed
A Pilot Study of the Treatment of VEGF-Signaling Pathway Inhibitor-Induced Hypertension With Direct Vasodilators, Minoxidil and Hydralazine [NCT00607477]2 participants (Actual)Interventional2008-01-31Terminated(stopped due to Study has been terminated due to poor accrual.)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]Phase 310,251 participants (Actual)Interventional1999-09-30Completed
A Phase II Study of Transcriptional Therapy With the DNA Demethylating Hydralazine and the HDAC Inhibitor Valproate Associated to Concomitant Cisplatin Chemoradiation in FIGO Stage III Cervical Cancer. [NCT00404326]Phase 218 participants Interventional2005-05-31Completed
A Phase II Clinical Study of Hydralazine and Valproic Acid in Combination With Neoadjuvant Cytotoxic Chemotherapy in Stage IIB and IIIA Breast Carcinoma [NCT00395655]Phase 243 participants Interventional2005-06-30Terminated
The Pathophysiology and Treatment of Supine Hypertension in Patients With Autonomic Failure [NCT00223717]Phase 1152 participants (Actual)Interventional2001-01-31Completed
A Randomised Trial to Establish the Effects of Early Intensive Blood Pressure Lowering on Death and Disability in Patients With Stroke Due to Acute Intracerebral Haemorrhage [NCT00226096]404 participants (Actual)Interventional2005-11-30Completed
Black Education and Treatment of Hypertension (BEAT HTN) [NCT00661895]Phase 499 participants (Actual)Interventional2005-08-31Completed
A Phase IV Randomized, Double-blind, Active-controlled, Single-center Study of the Safety and Effects on Cardiac Structure and Function of Hydralazine and Isosorbide Dinitrate in Patients With Hemodialysis Dependent ESRD [NCT02228408]Phase 417 participants (Actual)Interventional2017-08-28Completed
Randomized, Open-Label, Daily Dose, 2-sequence, 2-way Crossover Pharmacodynamic and Pharmacokinetic Study of BiDil XR Capsules and Commercial BiDil Tablets in Self-identified Black Patients, Who Are Slow Acetylators, With Heart Failure [NCT02522208]Phase 112 participants (Actual)Interventional2015-09-30Completed
Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients [NCT03423810]Early Phase 114 participants (Actual)Interventional2018-04-23Completed
Blood Pressure Management in Stroke Following Endovascular Treatment [NCT04484350]Phase 230 participants (Actual)Interventional2020-10-23Completed
An International Randomised Controlled Trial to Establish the Effects of Early Intensive Blood Pressure Lowering in Patients With Intracerebral Haemorrhage. [NCT00716079]2,839 participants (Actual)Interventional2008-09-30Completed
Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) Study [NCT02343393]Phase 3100 participants (Anticipated)Interventional2015-01-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00000620 (6) [back to overview]Death From Any Cause in the Glycemia Trial.
NCT00000620 (6) [back to overview]First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.
NCT00000620 (6) [back to overview]First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
NCT00000620 (6) [back to overview]Stroke in the Blood Pressure Trial.
NCT00661895 (1) [back to overview]Percentage of Subjects Achieving Blood Pressure Goals
NCT00716079 (2) [back to overview]A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS)
NCT00716079 (2) [back to overview]Death at 90 Days
NCT01516346 (5) [back to overview]Early Diastolic Mitral Annular Velocity
NCT01516346 (5) [back to overview]LV Mass
NCT01516346 (5) [back to overview]Myocardial Extracellular Volume Fraction
NCT01516346 (5) [back to overview]Quality of Life (Kansas City Cardiomyopathy Questionnaire Score)
NCT01516346 (5) [back to overview]Wave Reflection Magnitude
NCT02046395 (2) [back to overview]Change in the Level of Urinary Free Light Chains
NCT02046395 (2) [back to overview]Change in Urine Microalbumin Creatinine Ratio
NCT02228408 (6) [back to overview]Change in E' on TDI Echo From 0-6 Months
NCT02228408 (6) [back to overview]Change in LVMI
NCT02228408 (6) [back to overview]Efficacy-Change in Coronary Flow Reserve (CFR) From 0-6 Months
NCT02228408 (6) [back to overview]Number of Patients Completing Study From 0 to 6 Months
NCT02228408 (6) [back to overview]Rate of Hypotension, Serious Adverse Events, GI Events and Cardiovascular Death
NCT02228408 (6) [back to overview]Reduction in Drug Dose or Discontinuation of Study Drug
NCT04116112 (5) [back to overview]Final Infarct Volume
NCT04116112 (5) [back to overview]Number of Participants With Any Hemorrhagic Transformation
NCT04116112 (5) [back to overview]Number of Participants With Neurological Worsening Associated With Antihypertensive Treatment
NCT04116112 (5) [back to overview]Number of Participants With Symptomatic Hemorrhagic Transformation
NCT04116112 (5) [back to overview]Utility-weighted Modified Rankin Score

Death From Any Cause in the Glycemia Trial.

"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control391
Glycemia Trial: Standard Control327

[back to top]

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control503
Glycemia Trial: Standard Control543

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control208
BP Trial: Standard Control237

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate291
Lipid Trial: Placebo310

[back to top]

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate641
Lipid Trial: Placebo667

[back to top]

Stroke in the Blood Pressure Trial.

Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control36
BP Trial: Standard Control62

[back to top]

Percentage of Subjects Achieving Blood Pressure Goals

Percentage of subjects who achieved JNC-VII defined blood pressure goals. (NCT00661895)
Timeframe: 3 month intervals

Interventionpercentage of participants (Number)
Intervention81
Control57

[back to top]

A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS)

(NCT00716079)
Timeframe: 90 days

Interventionparticipants (Number)
Intensive Blood-Pressure Lowering719
Guideline-Recommended Blood-Pressure Lowering785

[back to top]

Death at 90 Days

(NCT00716079)
Timeframe: 90 days

Interventionparticipants (Number)
Intensive Blood-Pressure Lowering166
Guideline-Recommended Blood-Pressure Lowering170

[back to top]

Early Diastolic Mitral Annular Velocity

Diastolic mitral annular velocity measured at the basal septal mitral annulus (NCT01516346)
Timeframe: 24 weeks

Interventioncm/s (Mean)
Isosorbide Dinitrate6.8
Isosorbide Dinitrate + Hydralazine7.3
Placebo6.5

[back to top]

LV Mass

LV mass measured by MRI, in grams normalized to height in meters raised to the 1.7 power (m^1.7) (NCT01516346)
Timeframe: 24 weeks

Interventiongrams / meters ^1.7 (Mean)
Isosorbide Dinitrate68.2
Isosorbide Dinitrate + Hydralazine66.2
Placebo67.2

[back to top]

Myocardial Extracellular Volume Fraction

Myocardial extracellular volume, expressed as percent of total tissue volume, measured by MRI (T1 mapping pre and post-gadolinium administration) (NCT01516346)
Timeframe: 24 weeks

InterventionPercentage (Mean)
Isosorbide Dinitrate29.0
Isosorbide Dinitrate + Hydralazine31.3
Placebo29.5

[back to top]

Quality of Life (Kansas City Cardiomyopathy Questionnaire Score)

Quality of life, assessed with the Kansas City cardiomyopathy questionnaire (overall summary score, which ranges from 0 to 100). Higher values imply better quality of life. (NCT01516346)
Timeframe: 24 weeks

InterventionPoints on a scale (Mean)
Isosorbide Dinitrate62.1
Isosorbide Dinitrate + Hydralazine44.9
Placebo62.1

[back to top]

Wave Reflection Magnitude

The dimensionless ratio of backward (reflected) to forward wave amplitude. Higher values imply more wave reflection. (NCT01516346)
Timeframe: 24 weeks

Interventiondimensionless ratio (Mean)
Isosorbide Dinitrate0.38
Isosorbide Dinitrate + Hydralazine0.44
Placebo0.37

[back to top]

Change in the Level of Urinary Free Light Chains

In relation to kidney function and washout/reintroduction of ACE/ARB medication the level of urinary free light chains will be assessed. (NCT02046395)
Timeframe: Visit 1 (Baseline), Visit 3 (Day 60)

Interventionmg/g (Mean)
Alternate Antihypertensive Arm1.14

[back to top]

Change in Urine Microalbumin Creatinine Ratio

Kidney function will be assessed throughout the study to assess changes in function prior to the washout of ACE/ARB medication and reintroduction of the ACE/ARB medication. (NCT02046395)
Timeframe: Visit 1 (Baseline), Visit 3 (Day 60)

Interventionmg/g (Mean)
Alternate Antihypertensive Arm15

[back to top]

Change in E' on TDI Echo From 0-6 Months

Co-primary efficacy measure measured on Tissue Doppler Echocardiography (NCT02228408)
Timeframe: 0 to 6 months

Interventioncm/s (Mean)
Hydralazine/Isorsorbide Dinitrate0.56
Placebo-0.04

[back to top]

Change in LVMI

Change in left ventricular mass index between baseline and 6 months. (NCT02228408)
Timeframe: 0 to 6 months

Interventiong/m2 (Mean)
Hydralazine/Isorsorbide Dinitrate-10.6
Placebo-8

[back to top]

Efficacy-Change in Coronary Flow Reserve (CFR) From 0-6 Months

Primary Efficacy Measure-CFR measured on rest and stress Positron Emission Tomography (NCT02228408)
Timeframe: 0 to 6 months

Interventionratio (Mean)
Hydralazine/Isorsorbide Dinitrate-0.27
Placebo-0.03

[back to top]

Number of Patients Completing Study From 0 to 6 Months

Primary Feasibility Measure (NCT02228408)
Timeframe: 0 to 6 months

InterventionParticipants (Count of Participants)
Hydralazine/Isorsorbide Dinitrate6
Placebo10

[back to top]

Rate of Hypotension, Serious Adverse Events, GI Events and Cardiovascular Death

Rate of primary Safety Outcomes(hypotension, serious adverse events, GI events and CV death) (NCT02228408)
Timeframe: 6 months

,
InterventionParticipants (Count of Participants)
intradialytic hpypotensionSAENauseaCV death rate per patient year
Hydralazine/Isorsorbide Dinitrate1540
Placebo6330

[back to top]

Reduction in Drug Dose or Discontinuation of Study Drug

Primary Tolerability measure (NCT02228408)
Timeframe: 0 to 6 months

,
InterventionParticipants (Count of Participants)
discontinuationreduction
Hydralazine/Isorsorbide Dinitrate02
Placebo03

[back to top]

Final Infarct Volume

Infarct volume on diffusion-weighted MRI (or CT if MRI cannot be obtained) at 36 (+/-12) hrs after treatment initiation, adjusted for the baseline CT perfusion core infract volume. (NCT04116112)
Timeframe: 36 (+/-12) hrs after treatment initiation

InterventionCubic Centimeters (Mean)
Higher Systolic Blood Pressure (SBP) Target46.4
Lower SBP (<160 mmHg) Target50.7
Lower SBP (<140mmHg) Target32.4

[back to top]

Number of Participants With Any Hemorrhagic Transformation

Number of participants with any new bleeding within the infarcted brain tissue on 36(+/-12) hr MRI/CT scan after treatment initiation (NCT04116112)
Timeframe: 36(+/-12) hrs after treatment initiation

InterventionParticipants (Count of Participants)
Higher Systolic Blood Pressure (SBP) Target12
Lower SBP (<160 mmHg) Target12
Lower SBP (<140mmHg) Target14

[back to top]

Number of Participants With Neurological Worsening Associated With Antihypertensive Treatment

Defined as number of participants with 4 points of greater increase in NIH Stroke scale associated with reduction in SBP caused by anti-hypertensive treatment initiation or titration. (NCT04116112)
Timeframe: Treatment initiation to 24 hrs after treatment initiation

InterventionParticipants (Count of Participants)
Higher Systolic Blood Pressure (SBP) Target0
Lower SBP (<160 mmHg) Target0
Lower SBP (<140mmHg) Target0

[back to top]

Number of Participants With Symptomatic Hemorrhagic Transformation

Defined as number of participants with any new bleeding within the infarcted brain tissue and an NIH Stroke Scale worsening of 4 or more points associated with the bleeding within 36 (+/-12) hrs of treatment initiation (NCT04116112)
Timeframe: 36(+/-12) hrs after treatment initiation

InterventionParticipants (Count of Participants)
Higher Systolic Blood Pressure (SBP) Target2
Lower SBP (<160 mmHg) Target1
Lower SBP (<140mmHg) Target2

[back to top]

Utility-weighted Modified Rankin Score

"Modified Rankin score (mRS) is a scale for measuring the degree of disability or dependence of people who have suffered a stroke. 0 - no symptoms at all; 1 - no significant disability despite symptoms; able to carry out all usual duties and activities; 2- slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- moderate disability; requiring some help, but able to walk without assistance; 4 - moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5 - severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- dead.~Patient centered utility weights are applied to these scores as 1.0 for mRS level 0; 0.91 for mRS level 1; 0.76 for mRS level 2; 0.65 for mRS level 3; 0.33 for mRS level 4; 0 for mRS level 5; and 0 for mRS level 6. Unlike the mRS, the utility-weighted mRS runs from 0 to 1, with 0 being the worst." (NCT04116112)
Timeframe: 90 days after treatment initiation

Interventionunits on a scale (Range 0-1; 1=best) (Mean)
Higher Systolic Blood Pressure (SBP) Target0.58
Lower SBP (<160 mmHg) Target0.47
Lower SBP (<140mmHg) Target0.51

[back to top]